

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**



PCT/GB 01/02572

12



2001

INVESTOR IN PEOPLE

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

REC'D 04 JUL 2001

WIPO


PCT

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



Signed

Dated 19 June 2001

**PRIORITY
DOCUMENT**

SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

The
Patent
Office

THE PATENT OFFICE
M
13 DEC 2000
NEWPORT

13DEC00 E590969-7 D10057
P01/7700 0.00-0030306.5

1 / 77

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office

Cardiff Road
Newport
Gwent NP9 1RH

1. Your reference	00218 /GB		
2. Pat nt application number (The Patent Office will fill in this part)	0030306.5		13 DEC 2000
3. Full name, address and postcode of the or of each applicant (<u>underline all surnames</u>)	Eli Lilly and Company Lilly Corporate Center Indianapolis Indiana 46285 USA Patents ADP number (if you know it) If the applicant is a corporate body, give the country/state of its incorporation		
	428904002 IS		
4. Title of invention	COMPOUNDS		
5. Name of your agent (if you have one)	MARTIN ALEXANDER HAY		
"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)	13 QUEEN VICTORIA STREET MACCLESFIELD CHESHIRE SK11 6LP		
Patents ADP number (if you know it)	4245577001 7710858001 IS		
6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or each of these earlier applications and (if you know it) the or each application number	Country	Priority application number (if you know it)	Date of filing (day / month / year)
7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application	Number of earlier application		Date of filing (day / month / year)
8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if: a) any applicant named in part 3 is not an inventor, or b) there is an inventor who is not named as an applicant, or c) any named applicant is a corporate body See note (d))	No		

Patents Form 1/77

Enter the number of sheets for any of the following items you are filing with this form.
Do not count copies of the same document

Continuation sheets of this form	0
Description	79 ✓
Claim(s)	14 ✓ <i>W</i>
Abstract	1 ✓
Drawing(s)	0

10. If you are also filing any of the following, state how many against each item.

Priority documents	0
Translations of priority documents	0
Statement of inventorship and right to grant of a patent (<i>Patents Form 7/77</i>)	0
Request for preliminary examination and search (<i>Patents Form 9/77</i>)	0
Request for substantive examination (<i>Patents Form 10/77</i>)	0
Any other documents (please specify)	0

11. I/We request the grant of a patent on the basis of this application

Signature *Martin A Hay* Date: 12 Dec 2000

12. Name and daytime telephone number of person to contact in the United Kingdom
MARTIN A. HAY 01625 500057

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.

COMPOUNDS

This invention relates to compounds which are inhibitors of serine proteases and to pharmaceutical compositions thereof and their use in the treatment of the human or animal body.

The serine proteases are a group of proteolytic enzymes which have a common catalytic mechanism characterized by a particularly reactive Ser residue. Examples of serine proteases include trypsin, tryptase, chymotrypsin, elastase, thrombin, plasmin, kallikrein, Complement C1, acrosomal protease, lysosomal protease, cocoonase, α -lytic protease, protease A, protease B, serine carboxypeptidase II, subtilisin, urokinase, Factor VIIa, Factor IXa, and Factor Xa.

The serine proteases have been investigated extensively over a period of several decades and the therapeutic value of inhibitors of serine proteases is well understood.

Serine protease inhibitors play a central role in the regulation of a wide variety of physiological process including coagulation, fibrinolysis, fertilization, development, malignancy, neuromuscular patterning and inflammation. It is well known that these compounds inhibit a variety of circulating proteases as well as proteases that are activated or released in tissue. It is also becoming clear that serine protease inhibitors inhibit critical cellular processes, such as adhesion, migration, free radical production and apoptosis. In addition, animal experiments indicate that intravenously administered serine protease inhibitors, variants or cells expressing serine protease inhibitors, provide a protective effect against tissue damage.

Serine protease inhibitors have also been predicted to have potential beneficial uses in the treatment of disease in a wide variety of clinical areas such as oncology, neurology, haematology, pulmonary medicine, immunology, inflammation and infectious disease.

In particular serine protease inhibitors may be beneficial in the treatment of thrombotic diseases, asthma, emphysema, cirrhosis, arthritis, carcinoma, melanoma, restenosis, atheroma, trauma, shock and reperfusion injury.

Thus for example an inhibitor of Factor Xa has value as a therapeutic agent as an anticoagulant, e.g. in the treatment and prevention of thrombotic disorders. The use of a Factor Xa inhibitor as an anticoagulant is desirable in view of the
5 selectivity of its effect. Many clinically approved anticoagulants have been associated with adverse events owing to the non-specific nature of their effects on the coagulation cascade.

Also, there are well-known associations of $\alpha 1$ protease
10 inhibitor deficiency with emphysema and cirrhosis and C1 esterase inhibitor deficiency with angioedema.

It has now been found that certain aromatic compounds are particularly effective as inhibitors of serine proteases, especially proteases with negatively charged P1 specificity
15 pockets, and most especially the serine protease Factor Xa. The Factor Xa inhibitors of this invention are potentially useful for the prophylaxis or treatment of thrombotic disorders such as amongst others venous thrombosis, pulmonary embolism, arterial thrombosis, myocardial ischaemia,
20 myocardial infarction, and cerebral thrombosis. They potentially have benefit in the treatment of acute vessel closure associated with thrombolytic therapy and restenosis, e.g. after transluminal coronary angioplasty or bypass grafting of the coronary or peripheral arteries and in the
25 maintenance of vascular access patency in long term hemodialysis patients.

Factor Xa inhibitors of this invention may, with benefit, form part of a combination therapy with an anticoagulant with a different mode of action or with a thrombolytic agent.

30 It has been reported in WO99/11658 and WO99/11657 that certain benzamidine and aminoisoquinoline derivatives carrying a bulky lipophilic side chain are excellent inhibitors of serine proteases. Unfortunately, it has since been found that benzamidine compounds of WO 99/11658 in general demonstrate
35 poor oral bioavailability.


Surprisingly, it has now been found that certain other aromatic compounds also show inhibitory activity against serine proteases, in particular Factor Xa, despite the lack of

the amidino or 1-aminoisoquinoline functionality previously believed to be crucial for activity as a factor Xa inhibitor. Many of these compounds also possess other structural features that further distinguish them from the compounds of WO99/11658 5 and WO99/11657.

Where compounds of the invention have been tested, they have generally demonstrated superior oral bioavailability in comparison with benzamidines disclosed in WO 99/11658. Also, it has been found that the compounds of the invention perform 10 excellently in the prothrombin time assay (PT) when compared to aminoisoquinolines of similar factor Xa activity and structure. The PT assay is a coagulation assay and it is widely accepted that direct acting Factor Xa inhibitors which perform well in the PT assay are more likely to be good 15 antithrombotics.

In WO99/09053 certain 2-aminobenzamide compounds are disclosed as potential motilin receptor antagonists and in US 3268513 similar 2-aminobenzamide compounds are suggested as potential antibacterial agents. However, the novel compounds 20 of the present invention have not before been suggested as potential serine protease inhibitors.

Thus viewed from an one aspect the invention provides a serine protease inhibitor compound of formula (I)



wherein:

R₂ is a 5 or 6 membered aromatic carbon ring optionally interrupted by a nitrogen, oxygen or sulphur ring atom, optionally being substituted in the 3 and/or 4 position (in 30 relation to the point of attachment of X-X) by halo, nitro, thiol, haloalkoxy, hydrazido, alkylhydrazido, amino, cyano, haloalkyl, alkylthio, alkenyl, alkynyl, acylamino, tri or difluoromethoxy, carboxy, acyloxy, MeSO₂- or R₁, or the substituents at the 3 and 4 positions taken together form a 35 fused ring which is a 5 or 6 membered carbocyclic or heterocyclic ring optionally substituted by halo, haloalkoxy,

haloalkyl, cyano, nitro, amino, hydrazido, alkylthio, alkenyl, alkynyl or R_{1j} , and optionally substituted in the position alpha to the X-X group (i.e. 6 position for a six membered aromatic ring etc) by amino, hydroxy, halo, alkyl, carboxy, alkoxy, carbonyl, cyano, amido, aminoalkyl, alkoxy or alkylthio with the proviso that R_2 cannot be aminoisquinolyl;

each X independently is a C, N, O or S atom or a CO, CR_{1a}, C(R_{1a})₂ or NR_{1a} group, at least one X being C, CO, CR_{1a} or C(R_{1a})₂;

10 each R_{1a} independently represents hydrogen or hydroxyl, alkoxy, alkyl, aminoalkyl, hydroxyalkyl alkoxyalkyl, alkoxycarbonyl, alkylaminocarbonyl, alkoxycarbonylamino, acyloxymethoxycarbonyl or alkylamino optionally substituted by hydroxy, alkylamino, alkoxy, oxo, aryl or cycloalkyl;

15 R₁ is as defined for R_{1a}, provided that R₁ is not
unsubstituted aminoalkyl;

Y (the α -atom) is a nitrogen atom or a CR_{1b} group;

Cy is a saturated or unsaturated, mono or poly cyclic, homo or heterocyclic group, preferably containing 5 to 10 ring atoms and optionally substituted by groups R_{3a} or phenyl optionally substituted by R_{3a} or R_{3i}X_i;


each R_{3a} independently is R_{1c}, amino, halo, cyano, nitro, thiol, alkylthio, alkylsulphonyl, alkylsulphenyl, triazolyl, imidazolyl, tetrazolyl, hydrazido, alkylimidazolyl, thiazolyl, 25 alkylthiazolyl, alkyloxazolyl, oxazolyl, alkylsulphonamido, alkylaminosulphonyl, aminosulphonyl, haloalkoxy, haloalkyl, a group of the formula -C(X³)N(R¹¹)R¹² (wherein X³ is O or S; and R¹¹ and R¹² are independently selected from hydrogen, methyl or ethyl or together with the nitrogen atom to which they are 30 attached form a pyrrolidin-1-yl, piperidin-1-yl or morpholino group), or -OCH₂O- which is bonded to two adjacent ring atoms in Cy;

X_i is a bond, O, NH or CH_2 ;

R_{3i} is phenyl pyridyl or pyrimidinyl optionally
35 substituted by R_{3a};

R_{1b} , R_{1c} and R_{1j} are as defined for R_{1a} ; and

$$-L-L_p(D)_n \text{ is}$$



q is 1 or 2;

- Q is methylene; and R_q is NR_aR_b in which each of R_a and R_b independently is hydrogen or C_{1-3} alkyl; or one of R_a and R_b is hydrogen or methyl and the other of R_a and R_b is (3-6C)cycloalkyl, pyrid-4-yl, $-CH_2-R_c$ or $-CH_2-R_d$ in which R_c is pyridyl or phenyl (which phenyl may bear a fluoro, chloro, methyl, $CONH_2$, SO_2NH_2 , methylaminosulphonyl, dimethylaminosulphonyl, methylsulphonylamino, methoxy or methylsulphonyl substituent) and in which R_d is isopropyl or cyclopentyl, or NR_aR_b is azetidino, pyrrolidino, piperidino, morpholino, thiomorpholino, piperazino, or tetrahydro-1,4-diazepino [in which a pyrrolidino or piperidino may be a 3,4-didehydro derivative and in which a azetidino, pyrrolidino, piperidino, morpholino, thiomorpholino, piperazino, or tetrahydro-1,4-diazepino may be optionally substituted on a ring carbon atom by hydroxy, amino, (1-3C)alkoxy, (1-3C)hydroxyalkyl, (1-3C)alkyl, carboxy, methoxycarbonyl or ethoxycarbonyl (provided that the amino, hydroxy or alkoxy substituent is not on a ring carbon atom which is included in a double bond, or adjacent to a ring oxygen, sulfur or nitrogen atom) and in which the piperazino or tetrahydro-1,4-diazepino may bear a methyl group at the 4-position];
- or a physiologically-tolerable salt thereof, e.g. a halide, phosphate or sulphate salt or a salt with ammonium or an organic amine such as ethylamine or meglumine.

In the compounds of the invention, where the alpha atom is carbon it preferably has the conformation that would result from construction from a D- α -aminoacid $NH_2-CR_{1b}(Cy)-COOH$ where the NH_2 represents part of X-X. Likewise the fourth substituent R_{1b} at an alpha carbon is preferably a methyl or hydroxymethyl group or hydrogen.

In the compounds of the invention, unless otherwise indicated, aryl groups preferably contain 5 to 10 ring atoms optionally including 1, 2 or 3 heteroatoms selected from O, N and S; alkyl, alkenyl or alkynyl groups or alkylene moieties preferably contain up to 6 carbons, e.g. C₁₋₆ or C₁₋₃; cyclic groups preferably have ring sizes of 3 to 8 atoms; and fused multicyclic groups preferably contain 8 to 16 ring atoms.

Examples of particular values for R_{1a} are: hydrogen, methyl or ethyl. R_{1a} is preferably a hydrogen atom.


10 The linker group from the R₂ group to the alpha atom is preferably selected from -CH=CH-, -CONH-, -CONR_{1a}-, -NH-CO-, -NH-CH₂-, -CH₂-NH-, -CH₂O-, -OCH₂-, -COO-, -OC=O- and -CH₂CH₂-. Preferably, the X moiety nearest to the alpha atom is an NH or O atom, most preferably a NH group. The X moiety
15 alpha to the aromatic ring is preferably a carbon based group such as CH₂ or CO, preferably CO. Thus a particularly preferred linker X-X is -CONH-. In an alternative embodiment the linker is preferably a -OCH₂- group.

Examples of particular values for R_{1b} are: hydrogen, (1-
20 4C)alkyl, such as methyl or hydroxy(1-4C)alkyl, such as hydroxymethyl. R_{1b} is preferably a hydrogen atom.

The alpha atom (Y) is preferably a CH or C(CH₃) group, especially CH.

In the group -L-Lp(D)_n, preferably the azetidino,
25 pyrrolidino, piperidino, morpholino, thiomorpholino, piperazino or tetrahydro-1,4-diazepino in NR_aR_b is optionally substituted on a ring carbon atom by methyl, hydroxy or hydroxymethyl.

A preferred sub-group of compounds of formula I is that
30 in which wherein -L-Lp(D)_n is of the formula:



wherein:

q is 1 or 2;


Q is methylene; and R_q is NR_aR_b in which each of R_a and R_b

independently is hydrogen or C_{1-3} alkyl; or one of R_a and R_b is hydrogen or methyl and the other of R_a and R_b is $-CH_2-R_c$ or $-CH_2-R_d$ in which R_c is pyridyl or phenyl (which phenyl may bear a fluoro, chloro, methyl, $CONH_2$, SO_2NH_2 ,

- 5 methylaminosulphonyl, dimethylaminosulphonyl, methylsulphonylamino, methoxy or methylsulphonyl substituent) and in which R_d is isopropyl or cyclopentyl, or NR_aR_b is pyrrolidino, piperidino, morpholino, piperazino, or tetrahydro-1,4-diazepino in which a pyrrolidino or piperidino
 10 may be a 3,4-didehydro derivative and in which a pyrrolidino, piperidino, piperazino, or tetrahydro-1,4-diazepino may bear a methyl group at the 3- or 4-position.

q is preferably 2.

Preferably $-L-Lp(D)_n$ is of the formula:



15

wherein:


q is 1 or 2;

- Q is methylene; and R_q is NR_aR_b in which each of R_a and R_b independently is hydrogen or C_{1-3} alkyl; or one of R_a and R_b is
 20 hydrogen and the other is (3-6C)cycloalkyl or pyrid-4-yl; or NR_aR_b is azetidino, pyrrolidino, piperidino or piperazino [in which a pyrrolidino or piperidino may be a 3,4-didehydro derivative and in which a azetidino, pyrrolidino, piperidino or piperazino may be optionally substituted on a ring carbon
 25 atom by methyl, hydroxy or hydroxymethyl (provided that the hydroxy substituent is not on a ring carbon atom which is included in a double bond, or adjacent to a ring nitrogen atom) and in which the piperazino may bear a methyl group at the 4-position].

- 30 Preferably R_q is NR_aR_b in which R_a is hydrogen or C_{1-3} alkyl and R_b is C_{1-3} alkyl; or R_a is hydrogen and R_b is (3-6C)cycloalkyl or pyrid-4-yl; or NR_aR_b is azetidino, pyrrolidino, piperidino, morpholino, thiomorpholino or piperazino [in which a pyrrolidino, piperidino or piperazino
 35 may be optionally substituted on a ring carbon atom by hydroxy

or hydroxymethyl (provided that the hydroxy substituent is not on a ring carbon atom which is adjacent to a ring nitrogen atom) and in which the piperazino may bear a methyl group at the 4-position].

5 Most preferably, the group $L-Lp(D)_n$ is selected from




wherein:

10 m represents 0 or 1;

and when R_3 is present as a substituent on a saturated ring, it is selected from hydrogen, hydroxy, amino, (1-3C)alkoxy, (1-3C)hydroxyalkyl, (1-3C)alkyl, carboxy, methoxycarbonyl and ethoxycarbonyl.

15 For example specific groups of formula $L-Lp(D)_n$ include



Cy is preferably an optionally R_{3a} substituted: phenyl, pyridyl, thienyl, thiazolyl, naphthyl, piperidinyl, furanyl, 20 pyrrolyl, isoxazolyl, isothiazolyl, pyrazolyl, oxazolyl, imidazolyl, 1,2,4-thiadiazolyl, 1,3,4-thiadiazolyl, pyrimidinyl, pyridazinyl, quinoloyl, isoquinolyl, benzofuryl, benzothienyl or cycloalkyl group, or a phenyl group

substituted by $R_{3i}X_i$ in which X_i is a bond, O, NH or CH_2 and R_{3i} is phenyl, pyridyl or pyrimidinyl optionally substituted by R_{3a} .

The cyclic group attached to the alpha carbon may thus be
5 an optionally R_{3a} substituted phenyl, pyridyl (such as pyrid-2-yl, pyrid-3-yl or pyrid-4-yl), thienyl (such as thien-2-yl or thien-3-yl), thiazolyl (such as thiazol-2-yl, thiazol-4-yl or thiazol-5-yl), naphthyl (such as naphth-1-yl), piperidinyl (such as piperidin-4-yl) or cycloalkyl, such as a cyclohexyl
10 group.

Examples of values for Cy when it represents phenyl substituted by $R_{3i}X_i$ are 3-(2-pyridyl)phenyl, 3-(3-pyridylphenyl and 3-(4-pyridylphenyl).

Examples of particular values for R_{3a} are:-

15 hydrogen;

hydroxyl;

for alkoxy: methoxy or ethoxy;

for alkyl optionally substituted by hydroxy, alkylamino, alkoxy, oxo, aryl or cycloalkyl: alkyl, such as methyl or

20 ethyl, or alkylaminoalkyl, such as methylaminomethyl or dimethylaminomethyl;

for hydroxyalkyl optionally substituted by hydroxy, alkylamino, alkoxy, oxo, aryl or cycloalkyl: hydroxymethyl or carboxy;

25 for alkoxyalkyl: methoxymethyl;

for alkoxy carbonyl: methoxycarbonyl or ethoxycarbonyl;

for alkylaminocarbonyl: methylaminocarbonyl or dimethylaminocarbonyl;

30 for aminoalkyl optionally substituted by hydroxy, alkylamino, alkoxy, oxo, aryl or cycloalkyl: aminomethyl, $CONH_2$ or CH_2CONH_2 ;

for alkylamino optionally substituted by hydroxy, alkylamino, alkoxy, oxo, aryl or cycloalkyl: (1-6C)alkanoylamino, such as acetylamino;

for alkoxy carbonylamino: methoxycarbonylamino, ethoxycarbonylamino or t-butoxycarbonylamino;

amino;

for halo: fluoro, chloro or bromo;

cyano;

- nitro;
thiol;
for alkylthio: methylthio;
for alkylsulphonyl: methylsulphonyl or ethylsulphonyl;
5 for alkylsulphenyl: methylsulphenyl;
for alkylsulphonamido: methylsulphonylamido or
ethylsulphonylamido;
for alkylaminosulphonyl: methylaminosulphonyl or
ethylaminosulphonyl;
10 aminosulphonyl;
for haloalkoxy: trifluoromethoxy;
for haloalkyl: trifluoromethyl;
for a group of formula $-C(X^3)N(R^{11})R^{12}$: pyrrolidin-1-ylcarbonyl,
piperidin-1-ylcarbonyl or morpholin-1-ylcarbonyl; and
15 $-OCH_2O-$ which is bonded to two adjacent ring atoms in Cy.

Examples of particular values for R_{1C} are:


- hydrogen;
hydroxyl;
for alkoxy: methoxy or ethoxy;
20 for alkyl optionally substituted by hydroxy, alkylamino,
alkoxy, oxo, aryl or cycloalkyl: alkyl, such as methyl or
ethyl, or alkylaminoalkyl, such as methylaminomethyl or
dimethylaminomethyl;
for hydroxyalkyl: hydroxymethyl;
25 for alkoxyalkyl: methoxymethyl;
for alkoxycarbonyl: methoxycarbonyl or ethoxycarbonyl;
for alkylaminocarbonyl: methylaminocarbonyl or
dimethylaminocarbonyl;
for alkoxycarbonylamino: methoxycarbonylamino,
30 ethoxycarbonylamino or t-butoxycarbonylamino;
for alkylamino optionally substituted by hydroxy, alkylamino,
alkoxy, oxo, aryl or cycloalkyl: (1-6C)alkanoylamino, such as
acetilylamino; and
for aminoalkyl substituted by hydroxy, alkylamino, alkoxy,
35 oxo, aryl or cycloalkyl: aminomethyl, $CONH_2$ or CH_2CONH_2 .

Preferably R_{3a} is hydrogen, hydroxyl, methoxy, methyl,
amino, fluoro, chloro, ethylsulphonylamino, amido or
methylaminocarbonyl.

Examples of values for R_{31} are phenyl, pyrid-2-yl, pyrid-3-yl, pyrid-4-yl, pyrimid-2-yl and pyrimid-6-yl.

Examples of particular values for Cy are phenyl, 4-aminophenyl, 4-amidophenyl, 4-(N-methyl)amidophenyl, 4-(N,N-dimethyl)amidophenyl, 2-chlorophenyl, 2-methylphenyl, 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 4-hydroxyphenyl, 2-methoxyphenyl, 4-methoxyphenyl, 4-carboxyphenyl, 3-ethylsulphonylaminophenyl, thien-2-yl, thien-3-yl, thiazol-4-yl, thiazol-5-yl, 2-methylthiazol-4-yl, pyrid-2-yl, pyrid-3-yl, pyrid-4-yl, piperidin-4-yl, 1-methylpiperidin-4-yl, cyclohexyl and naphth-1-yl.

Particular mention is made of the following values for Cy:



wherein:

X' is selected from O, S and NMe;

5 X'' is selected from O and S;

X''' is selected from O, S, NH and NMe;

Y' is selected from hydrogen, amino and methyl;

R_o is selected from hydrogen, methyl, fluoro, chloro, trifluoromethyl, methoxy, methylthio, methylsulphinyl and

10 methylsulphonyl;

R_m is selected from hydrogen, methyl, fluoro, chloro, trifluoromethyl, methoxy, methylthio, methylsulphinyl, methylsulphonyl, carboxy, methoxycarbonyl and a group of the formula -C(X³)N(R¹¹)R¹² (wherein X³ is O or S, and R¹¹ and R¹² are

independently selected from hydrogen, methyl or ethyl or together with the nitrogen atom to which they are attached form a pyrrolidin-1-yl, piperidin-1-yl or morpholino group);

R_p is selected from hydrogen and fluoro; or

5 R_o and R_m or R_m and R_p form an -OCH₂O- group; or

R_o and R_m together with the ring to which they are attached form a 5 or 6 membered aryl or heteroaryl ring (wherein the heteroaryl ring contains 1 or 2 heteroatoms selected from nitrogen, oxygen and sulfur); and

10 one of R_{o1} and R_{o2} is hydrogen and the other is R_o .

wherein Cy is selected from phenyl (optionally substituted by ethyl, prop-2-yl, phenoxy, hydroxy, ethoxy, benzyloxy, prop-2-yloxy, nitro, amino, acetylamino, methylsulfonylamino, dimethylamino, chloro, methoxy, trifluoromethyl, methylthio,

15 methylsulfonyl, tert-butylthio, tert-butylsulfonyl, aminosulfonyl or carbamoyl), pyridyl, thienyl, furanyl, imidazolyl, thiazolyl (optionally substituted by amino or methyl), naphthyl, isoquinolyl and quinolyl.


Preferably Cy is selected from phenyl, 2-chlorophenyl, 2-
20 methoxyphenyl, 4-carbamoylphenyl, pyrid-2-yl, pyrid-4-yl, thien-2-yl, thien-3-yl, furan-2-yl, furan-3-yl, imidazol-2-yl, thiazol-2-yl, thiazol-4-yl, 2-amino-thiazol-4-yl, thiazol-5-yl, naph-1-thyl, isoquinolin-5-yl, isoquinolin-8-yl, quinolin-4-yl, quinolin-5-yl and quinolin-8-yl.

25 More preferably Cy is selected from phenyl, 2-methoxyphenyl, 4-carbamoylphenyl, pyrid-2-yl, thien-2-yl, thien-3-yl, furan-2-yl, furan-3-yl, imidazol-2-yl, thiazol-2-yl, thiazol-4-yl, thiazol-5-yl and quinolin-4-yl.

A value for Cy of particular interest is phenyl.

30 Referring to the group R_2 , examples of a 5 or 6 membered aromatic carbon ring optionally interrupted by a nitrogen, oxygen or sulphur ring atom are phenyl; pyrrolyl, such as 2-pyrrolyl; pyridyl, such as 3-pyridyl; pyrazinyl, such as 2-pyrazinyl; furyl, such as 2-furyl; and thienyl, such as 2-
35 thienyl or 3-thienyl. Preferably the ring is interrupted (i.e. a carbon atom is replaced) by at most one heteroatom. More preferably the ring is phenyl, 2-thienyl or 2-pyrrolyl. Most preferably, the ring is phenyl.

When the ring is phenyl, the group R_2 may be a group of formula



in which R_5 is amino, hydroxy or hydrogen, and R_6 and R_7 which
 5 may be the same or different represent halo, nitro, thiol, cyano, haloalkyl, haloalkoxy, amido, hydrazido, amino, alkylthio, alkenyl, alkynyl or R_1 or taken together form a 5 or 6 membered fused carbocyclic ring or 5 membered heterocyclic ring, which may itself be substituted by R_{1j} ,
 10 amino, halo, cyano, nitro, thiol, alkylthio, haloalkyl, haloalkoxy.

When the substituents at the 3 and 4 positions taken together form a fused ring which is a 5 or 6 membered carbocyclic or heterocyclic ring, examples of the resultant
 15 bicyclic ring are naphthyl, such as 2-naphthyl; benzimidazolyl, such as benzimidazol-5-yl or benzimidazol-6-yl; isoquinolinyl, such as isoquinolin-7-yl; indolyl, such as indol-2-yl, indol-5-yl or indol-6-yl; indazolyl, such as indazol-5-yl; indazol-6-yl; 3,4-methylenedioxyphenyl;
 20 dihydroindolyl, such as 2,3-dihydroindol-6-yl; benzothiazolyl, such as benzothiazol-2-yl or benzothiazol-6-yl; benzo[b]thiophenyl, such as benzo[b]thiophen-2-yl; benzofuryl, such as benzofur-2-yl; imidazo[1,2-a]pyrimidinyl, such as imidazo[1,2-a]pyrimidin-2-yl; tetrahydroimidazo[1,2-a]pyrimidinyl, such as tetrahydroimidazo[1,2-a]pyrimidin-2-yl;
 25 and benzisoxazolyl, such as benzisoxazol-5-yl.

Preferably R_2 is phenyl, thien-2-yl, naphthyl, indol-2-yl, indol-6-yl, benzo[b]furan-5-yl, benzo[b]thiophen-2-yl or benzimidazol-2-yl, optionally substituted as defined
 30 hereinabove.

R_2 preferably represents:

(i) phenyl optionally being substituted in the 3 and/or 4 position by halo, nitro, thiol, haloalkoxy, hydrazido, alkylhydrazido, amino, cyano, haloalkyl, alkylthio, alkenyl, alkynyl, acylamino, tri or difluoromethoxy, carboxy, acyloxy, 5 MeSO₂- or R₁, and optionally substituted at the 6 position by amino, hydroxy, halo, alkyl, carboxy, alkoxycarbonyl, cyano, amido, aminoalkyl, alkoxy or alkylthio;

(ii) naphth-2-yl optionally substituted at the 6 or 7 position by halo, haloalkoxy, haloalkyl, cyano, nitro, amino, 10 hydrazido, alkylthio, alkenyl, alkynyl or R_{1j} and optionally substituted at the 3 position by amino, hydroxy, halo, alkyl, carboxy, cyano, amido, aminoalkyl, alkoxy or alkylthio;

(iii) isoquinolin-7-yl, indol-5-yl, indol-6-yl, indazol-5-yl, indazol-6-yl, benzothiazol-6-yl or benzisoxazol-5-yl 15 optionally substituted at the 3 position by halo, haloalkoxy, haloalkyl, cyano, nitro, amino, hydrazido, alkylthio, alkenyl, alkynyl or R_{1j};

(iv) benzimidazol-5-yl or benzothiazol-6-yl optionally substituted at the 2 position by amino;

20 (v) thien-2-yl or thien-3-yl optionally substituted at the 4 or 5 position by halo, haloalkoxy, haloalkyl, cyano, nitro, amino, hydrazido, alkylthio, alkenyl, alkynyl or R₁;

(vi) 3,4-methylenedioxyphenyl, 2,3-dihydroindol-6-yl, 3,3-dichloro-2-oxo-indol-6-yl or 1-methyl-3-aminoindazol-5-yl;

25 (vii) benzothiazol-2-yl, imidazo[1,2-a]pyrimidin-2-yl or tetrahydroimidazo[1,2-a]pyrimidin-2-yl;

(viii) pyrazol-2-yl optionally substituted at the 5 position by halo, haloalkoxy, haloalkyl, cyano, nitro, amino, hydrazido, alkylthio, alkenyl, alkynyl or R₁;

30 (ix) pyrid-2-yl optionally substituted at the 5 position by halo, haloalkoxy, haloalkyl, cyano, nitro, amino, hydrazido, alkylthio, alkenyl, alkynyl or R₁;

(x) pyrid-3-yl optionally substituted at the 6 position by halo, haloalkoxy, haloalkyl, cyano, nitro, amino, 35 hydrazido, alkylthio, alkenyl, alkynyl or R₁;

(xi) benzofur-2-yl optionally substituted at the 3 position by amino, hydroxy, halo, alkyl, carboxy, cyano, amido, aminoalkyl, alkoxy or alkylthio and at the 5 or 6

position by halo, haloalkoxy, haloalkyl, cyano, nitro, amino, hydrazido, alkylthio, alkenyl, alkynyl or R_{1j} ;

(xii) indol-2-yl optionally substituted on the indole nitrogen atom by alkyl and optionally substituted at the 5 or 6 position by halo, haloalkoxy, haloalkyl, cyano, nitro, amino, hydrazido, alkylthio, alkenyl, alkynyl or R_{1j} ;

(xiii) indol-6-yl substituted at the 5 position by amino, hydroxy, halo (such as fluoro or chloro), alkyl, carboxy, alkoxycarbonyl, cyano, amido, aminoalkyl, alkoxy or alkylthio and optionally substituted at the 3 position by halo (such as chloro), haloalkoxy, haloalkyl, cyano, nitro, amino, hydrazido, alkylthio, alkenyl, alkynyl or R_{1j} ; or

(xiv) benzo[b]thiophen-2-yl optionally substituted at the 3 position by amino, hydroxy, halo, alkyl, carboxy, cyano, amido, aminoalkyl, alkoxy or alkylthio and at the 5 or 6 position by halo, haloalkoxy, haloalkyl, cyano, nitro, amino, hydrazido, alkylthio, alkenyl, alkynyl or R_{1j} .

Examples of particular values for substituents that may be present on R_2 are:

for halo: fluoro, chloro, bromo or iodo;
nitro;
thiol;

for haloalkoxy: difluoromethoxy or trifluoromethoxy;
hydrazido;

for alkylhydrazido: methylhydrazido;
amino;
cyano;

for haloalkyl: trifluoromethyl;
for alkylthio: methylthio;

for alkenyl: vinyl;
for alkynyl: ethynyl;
for acylamino: acetylamino;
carboxy;
for acyloxy: acetoxy;

hydroxy;
for alkyl: methyl or ethyl;
amido (CONH_2);
for aminoalkyl: aminomethyl; and

for alkoxy: methoxy or ethoxy.

Preferably R_2 is optionally substituted by 1 or 2 substituents selected from fluoro, chloro, amino, methyl, ethyl and methoxy.

5 Examples of particular values for R_1 are:

hydrogen;

hydroxy;

for alkoxy: methoxy or ethoxy;

10 for alkyl optionally substituted by hydroxy, alkylamino, alkoxy, oxo, aryl or cycloalkyl: alkyl, such as methyl or ethyl, alkylaminoalkyl, such as dimethylaminomethyl, or alkanoyl, such as acetyl;

for hydroxyalkyl: hydroxymethyl;

for alkoxyalkyl: methoxymethyl;

15 for alkoxycarbonyl: methoxycarbonyl;

for alkylaminocarbonyl: methylaminocarbonyl;

for alkylamino: methylamino, ethylamino or dimethylamino;

for hydroxyalkyl substituted by hydroxy, alkylamino, alkoxy, oxo, aryl or cycloalkyl: carboxyl or carboxymethyl; and

20 for aminoalkyl substituted by hydroxy, alkylamino, alkoxy, oxo, aryl or cycloalkyl: amido (CONH_2) or amidomethyl.

Examples of particular values for R_{1j} are:

hydrogen;

hydroxy;

25 for alkoxy: methoxy or ethoxy;

for alkyl optionally substituted by hydroxy, alkylamino, alkoxy, oxo, aryl or cycloalkyl: alkyl, such as methyl or ethyl, or alkanoyl, such as acetyl;

for hydroxyalkyl: hydroxymethyl;

30 for alkoxyalkyl: methoxymethyl;

for alkoxycarbonyl: methoxycarbonyl;

for alkylamino: methylamino, ethylamino or dimethylamino;

for hydroxyalkyl substituted by hydroxy, alkylamino, alkoxy, oxo, aryl or cycloalkyl: carboxyl or carboxymethyl; and

35 for aminoalkyl substituted by hydroxy, alkylamino, alkoxy, oxo, aryl or cycloalkyl: amido (CONH_2) or amidomethyl.

More preferably R_2 represents:

- (i) phenyl optionally being substituted in the 3 and/or 4 position by fluoro, chloro, bromo, iodo, nitro, difluoromethoxy, trifluoromethoxy, amino, cyano, trifluoromethyl, methylthio, vinyl, carboxy, acetoxy, MeSO₂-,
5 hydroxy, methoxy, ethoxy, methyl, methoxycarbonyl, methylamino, ethylamino or amido, and optionally substituted at the 6 position by amino, hydroxy, fluoro, methoxycarbonyl, cyano or aminomethyl (preferably phenyl substituted in the 4 position by chloro, amino, vinyl, methylamino, methyl or
10 methoxy, optionally at the 3 position with amino or hydroxy, and optionally at the 6 position with amino or hydroxy);
- (ii) naphth-2-yl optionally substituted at the 6, position by hydroxy and optionally substituted at the 3 position by amino or hydroxy;
- 15 (iii) isoquinolin-7-yl, indol-5-yl, indol-6-yl, indazol-5-yl, indazol-6-yl, benzothiazol-6-yl or benzisoxazol-5-yl optionally substituted at the 3 position by chloro, bromo, amino, methyl or methoxy (preferably indol-6-yl optionally substituted at the 3 position by chloro, bromo, methyl or
20 methoxy);
- (iv) benzimidazol-5-yl or benzothiazol-6-yl optionally substituted at the 2 position by amino;
- (v) thien-2-yl or thien-3-yl optionally substituted at the 4 or 5 position by methylthio, methyl or acetyl;
- 25 (vi) 3,4-methylenedioxyphenyl, 2,3-dihydroindol-6-yl, 3,3-dichloro-2-oxo-indol-6-yl or 1-methyl-3-aminoindazol-5-yl;
- (vii) benzothiazol-2-yl, imidazo[1,2-a]pyrimidin-2-yl or tetrahydroimidazo[1,2-a]pyrimidin-2-yl;
- (viii) pyrazol-2-yl substituted at the 5 position by
30 methyl;
- (ix) pyrid-2-yl optionally substituted at the 6 position by chloro;
- (x) pyrid-3-yl optionally substituted at the 4 position by chloro;
- 35 (xi) benzofur-2-yl optionally substituted at the 3 position by chloro, methyl or methoxy, at the 5 or 6 position by methyl and at the 6 position by methoxy;

(xii) indol-2-yl optionally substituted on the indole nitrogen atom by methyl and optionally substituted at the 5 or 6 position by fluoro, chloro, bromo, methyl or methoxy;

(xiii) indol-6-yl substituted at the 5 position by 5 chloro, fluoro or hydroxy and optionally substituted at the 3 position by chloro or methyl; or

(xiv) benzo[b]thiophen-2-yl optionally substituted at the 3 position by fluoro, chloro or methyl, and optionally substituted at the 5 or 6 position by fluoro, chloro, methyl, 10 hydroxy, or methoxy.

Examples of particular values for R₂ are:

(i) phenyl, 2-aminophenyl, 3-aminophenyl, 2-amino-3-fluorophenyl, 2-amino-4-fluorophenyl, 2-amino-4-chlorophenyl, 2-amino-3-bromophenyl, 2-amino-3-nitrophenyl, 2-amino-4-15 nitrophenyl, 3,4-dimethoxy-5-aminophenyl, 2-amino-4-methylphenyl, 2-amino-3-methylphenyl, 2-amino-3-methoxyphenyl, 3,4-diaminophenyl, 3,5-diaminophenyl, 3-amino-4-fluorophenyl, 3-amino-4-chlorophenyl, 3-amino-4-bromophenyl, 3-amino-4-hydroxyphenyl, 3-amino-4-carboxymethylphenyl, 3-amino-4-20 methylphenyl, 3-amino-4-methoxyphenyl, 2-fluorophenyl, 4-fluoro-3-cyanophenyl, 3-chlorophenyl, 3-chloro-4-hydroxyphenyl, 3-chloro-5-hydroxyphenyl, 4-chlorophenyl, 4-chloro-2-hydroxyphenyl, 4-chloro-3-hydroxyphenyl, 4-chloro-3-methylphenyl, 4-chloro-3-methoxyphenyl, 4-bromophenyl, 4-25 bromo-3-methylphenyl, 4-iodophenyl, 2-cyanophenyl, 3-cyanophenyl, 4-cyanophenyl, 3-cyano-5-aminophenyl, 2-hydroxyphenyl, 2-hydroxy-4-methoxyphenyl, 3-hydroxyphenyl, 3-hydroxy-4-methylphenyl, 2,4-dihydroxyphenyl, 3,4-dihydroxyphenyl, 3-hydroxy-4-methoxyphenyl, 4-30 difluoromethoxyphenyl, 4-trifluoromethoxyphenyl, 4-trifluoromethylphenyl, 4-methylthiophenyl, 4-methoxycarbonylphenyl, 4-acetoxyphenyl, 4-methanesulfonylphenyl, 3-methylphenyl, 3-methyl-5-aminophenyl, 4-methylphenyl, 4-vinylphenyl, 4-methoxyphenyl, 4-35 ethoxyphenyl, 4-methoxy-3-chlorophenyl, 4-methoxy-3-methylphenyl, 3-methylaminophenyl, 4-methylaminophenyl, 4-ethylaminophenyl or 2-aminomethylphenyl;

(ii) naphth-2-yl, 3-aminonaphth-2-yl, 3-hydroxynaphth-2-yl or 6-hydroxynaphth-2-yl;

(iii) isoquinolin-7-yl, indol-5-yl, indol-6-yl, 3-chloroindol-6-yl, 3-bromoindol-6-yl, 3-methylindol-6-yl, 3-methoxyindol-6-yl, indazol-5-yl, 3-aminoindazol-5-yl, indazol-6-yl, benzothiazol-6-yl, 3-aminobenzisoxazol-5-yl;

(iv) benzimidazol-5-yl, 2-aminobenzimidazol-5-yl, or benzothiazol-6-yl;

(v) thien-2-yl, 5-methylthien-2-yl, 5-methylthio-thien-2-yl, 5-acetylthien-2-yl or thien-3-yl;

(vi) 3,4-methylenedioxyphenyl, 2,3-dihydroindol-6-yl, 3,3-dichloro-2-oxo-indol-6-yl or 1-methyl-3-aminoindazol-5-yl;

(vii) benzothiazol-2-yl, imidazo[1,2-a]pyrimidin-2-yl or tetrahydroimidazo[1,2-a]pyrimidin-2-yl;

15 (viii) 5-methylpyrazol-2-yl;

(ix) 5-chloropyrid-2-yl;

(x) pyrid-3-yl, 6-chloropyrid-3-yl;


(xi) benzofur-2-yl, 5-chlorobenzofur-2-yl, 3-methylbenzofur-2-yl, 5-methylbenzofur-2-yl, 6-methoxybenzofur-20 2-yl;

(xii) indol-2-yl, 5-fluoroindol-2-yl, 5-chloroindol-2-yl, 5-methylindol-2-yl, 5-methoxyindol-2-yl, 6-methoxyindol-2-yl and 1-methyl-indol-2-yl;

(xiii) 5-fluoroindol-6-yl; or

25 (xiv) benzo[b]thiophen-2-yl, 5-chloro- benzo[b]thiophen-2-yl or 6-chlorobenzo[b]thiophen-2-yl.

R₂ may, for example, be selected from one of the formula (A') to (H'):



wherein X_4 is O or S, R_{13} is selected from hydrogen, chloro or methyl and R_{14} is selected from hydrogen, methyl, ethyl, 5 fluoro, chloro, and methoxy and R_{15} is selected from hydrogen, methyl, fluoro, chloro and amino.

Preferably R_2 is of the formula (A') (wherein R_{14} is selected from hydrogen, methyl, ethyl, fluoro, chloro, and methoxy and R_{15} is selected from hydrogen, methyl, fluoro, 10 chloro and amino) or of the formula (B') (wherein R_{13} is chloro) or of the formula (C') (wherein R_{13} is selected from hydrogen, methyl and chloro) or of the formula (D') (wherein R_{13} is selected from hydrogen and chloro) or of the formula (E') (wherein R_{13} is hydrogen) or of the formula (G') (wherein 15 R_{13} is chloro).

More preferably R_2 is 4-methoxyphenyl, 5-chloroindol-2-yl, 3-chloroindol-6-yl, indol-6-yl or 3-methylindol-6-yl.

R_2 is preferably of the formula (A') and R_{14} and R_{15} are as defined hereinabove. More preferably R_2 is of the formula (A') and R_{14} is methoxy and R_{15} is hydrogen.

It is preferred that at least one of R_6 and R_7 be other than hydrogen and that R_6 , if present, is preferably a substituent containing one or more polar hydrogens such as hydroxy, amino, alkylamino, alkylaminoalkyl, aminocarbonyl, alkylaminocarbonyl, hydrazo and alkylhydrazo; alternatively R_6 and R_7 are joined together in the formation of a naphthyl or indolyl or azaindolyl or diazaindolyl group.

It is especially preferred that R_6 be amino and R_7 be chloro, bromo, methyl, methoxy or vinyl; or that R_6 and R_7 taken together form an indolyl ring with the NH at the 6-position or taken together form a naphthyl ring.


The compounds of the invention may be prepared by conventional chemical synthetic routes or by routes as illustrated by the following examples.

The compounds of the formula (I) may be prepared by forming the -X-X- bond from appropriate intermediates. For example, when -X-X- is -CONH- or -CO-NR_{1a}-, by reacting a compound of the formula (10): $H_2N-Y-(Cy)-L-Lp(D)_n$ with a compound of the formula R_2-COOH , under conditions known for the formation of an amide bond. The reaction is conveniently carried out in the presence of a benzotriazole-based reagent such as 1-hydroxybenzotriazole or 1-hydroxy-7-azabenzotriazole, in an inert organic solvent such as dimethylformamide and/or methylene chloride. The reaction mixture is usually taken to 0°C and then a dehydrating agent such as dicyclohexylcarbodiimide or 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide added. Other suitable reagents and solvents are known in the art.

Compounds wherein -X-X- is -NHCO- or -NHCH₂- may be formed from the appropriate intermediates using reaction conditions for the formation of an amide bond as described above and if necessary subsequent reduction of the resulting amide bond.

Compounds of the formula (I) wherein -X-X- is of the formula -CH₂NH- may be prepared by reducing the corresponding

compound of the formula (I) wherein -X-X- is -CONH-, or by reaction of a compound of formula (10)



with a compound of the formula R_2CHO and reducing the intermediate of formula (I) where X-X is C=N- with, for example, sodium cyanoborohydride.

When -X-X- is -CH=CH-, the compounds of the formula (I) may be prepared using the Wittig or Horner-Emmous reactions. The corresponding compound in which -X-X- is -CH₂CH₂- can be formed by reduction of the -CH=CH- group, for example with hydrogen over a palladium-on-carbon catalyst.


An -X-X- bond of the formula -COO- or -OC(O)- may be formed by reacting the appropriate hydroxy and activated carboxylic acid (e.g. acid chloride or reactive ester) intermediates under conditions known for ester bond formation.

Alternatively, a hydroxy and a carboxylic acid intermediate could be reacted together in the presence of diethylazodicarboxylate/triphenylphosphine.

An -X-X- bond of the formula -CH₂O- or -OCH₂- may be formed by reacting the appropriate hydroxy intermediate with the appropriate alkyl halide in the presence of a base. Conditions for the formation of an ether bond are known in the art.

These reactions can also be used to form intermediates, which contain one of the above -X-X- bonds.

Compounds of the formula (I) may also be prepared by introducing the Lp(D)_n group into a compound of the formula (11):



30


Reactive groups in Lp(D)_n, which could cause side-reactions can of course be protected. The reaction between the compound (11) and Lp(D)_n is conveniently carried out in an inert organic solvent, in the presence of an organic base such as an amine (e.g. ethyldiisopropylamine), additionally in the presence of a reagent such as diethylcyanophosphonate.

Intermediates which already contain the Lp(D)_n group may be prepared from the appropriate carboxy compound using


similar reaction conditions to those described above.

Compounds of the formula (I) can also be prepared by reacting a compound of the formula (12):

5



or (13):



10

(wherein X^5 is a leaving group such as tosyloxy, mesyloxy or halo) with a compound of formula HNR_aR_b . The reaction between the compound of formula (13) and HNR_aR_b may be carried out using conditions similar to those described in Examples 1 to 5. The reaction between the compound of formula (12) and HNR_aR_b may be carried out in an inert organic solvent such as THF, in the presence of an inorganic base such as potassium carbonate, and preferably in the presence of sodium iodide. The reaction usually takes place at or near reflux of THF.

Intermediates containing the Lp(D)_n group can also be formed using these reactions from appropriate intermediates, although normally the introduction of the HNR_aR_b group is the last step in the synthesis.

- Hence the present invention also provides a process for the preparation of a compound of formula (I) comprising:
- when $-\text{X-X}$ is $-\text{CONH}-$, reacting a compound of formula (10) with a compound of formula $\text{R}_2\text{-COOH}$, under amide bond-forming conditions;
 - reacting a compound of formula (11) with a compound of formula Lp(D)_n under amide bond-forming conditions; or
 - reacting a compound of formula (12) or (13) with a compound of formula HNR_aR_b ;
- wherein R_2 , R_a , R_b and Lp(D)_n are as hereinabove defined and

formulae (10), (11), (12) and (13) are as hereinabove defined.


A compound of the formula (12) or (13) may be formed from the corresponding hydroxymethyl compound. Oxidation of the hydroxymethyl compound with a suitable mild oxidising agent for the formation of aldehydes, such as N-methylmorpholine oxide in the presence of tetrapropylammonium perruthonate, can be used to form a compound of the formula (12).

Other possible oxidising agents include manganese dioxide or DMSO/oxalyl chloride or DMSO/SO₂ or Dess-Martin reagent.

10 A compound of formula (13) can be formed from the hydroxymethyl compound by introducing the leaving group X. When X is mesyloxy or tosyloxy, the hydroxymethyl compound may be reacted with the mesyl or tosyl halide in the presence of an organic base, such as triethylamine, in an inert organic
15 solvent such as dichloromethane.

When -X-X is -CONH- and Y is CH, a compound of formula (I) may be prepared by a number of steps from an amino acid derivative using the reactions described above. For example, see Scheme I

Scheme 1



PG is an amino-protecting group

PG' is a carboxy-protecting group

An amino acid from Scheme I may be prepared (for example) by one or more of the following methods:

- (i) from aryl or heteroaryl aldehydes via the Strecker synthesis or modifications thereof, via Bucherer-Bergs hydantoin synthesis, or via the Ugi methodology ("Isonitrile Chemistry", Ugi I. Ed.; Academic: New York, 1971;145-1999, "Multicomponent Reactions with Isocyanides", Domling, A.;

- Ugi, I. *Angew. Chem. Int. Ed.* 2000, 39, 3168; "Amino Acid Derivatives by Multicomponent Reactions", Dyker, G. *Angew. Chem. Int. Ed. Engl.* 1997, 36, 1700; and also see "A new Class of Convertible Isocyanides in the Ugi Four-Component Reaction", Lindhorst, T.; Bock H.; Ugi, I. *Tetrahedron*, 1999, 55, 7411.) with removal and replacement of protecting groups;
- (ii) from styrenes via Sharpless methodology (*J. Am. Chem. Soc.* 1998, 120, 1207-1217)
- (iii) from aryl boronic acids via Petasis methodology (*Tetrahedron*, 1997, 53, 16463-16470) with removal and replacement of protecting groups;
- (iv) from aryl and heteroaryl acetic acids - via Evan's azidation (*Synthesis*, 1997, 536-540) or by oximation, followed by reduction and addition of protecting groups; or
- (v) from existing aryl glycines by manipulation of functional groups, for example, alkylation of hydroxy groups, palladium assisted carbonylation of triflates derived from hydroxy groups and further manipulation of the carboxylic esters to give carboxylic acids by hydrolysis, carboxamides by activation of the carboxylic acid and coupling with amines, amines via Curtius reaction on the carboxylic acid or
- (vi) from aliphatic, carbocyclic and non-aromatic heterocyclic aldehydes and ketones using a Horner-Emmons reaction with N-benzyloxycarbonyl)- α -phosphonoglycine trimethyl ester (*Synthesis*, 1992, 487-490), or by any other method known in the art.

A starting material for the preparation of a compound of formula (I), where the alpha atom is nitrogen, may be produced, for example, by reaction of a beta protected hydrazine (such protection to be chosen as to be compatible with the subsequent reagents to be employed) with phosgene, diphosgene, triphosgene or N,N'-carbonyl diimidazole to give a reactive compound of the type $\text{PGNHN}(\text{Cy})\text{COCl}$ or $\text{PGNHN}(\text{Cy})\text{CO-imidazole}$ (wherein PG is a protecting group).

This intermediate may be used as has been described above

for the carboxylic starting reagents where the alpha atom is carbon.

The skilled person will be aware that at certain stages in the synthesis of a compound of formula (I) it may be
 5 necessary to protect a reactive functional group in the molecule to prevent unwanted side-reactions.

The protection of amino and carboxylic acid groups is described in McOmie, Protecting Groups in Organic Chemistry, Plenum Press, NY, 1973, and Greene and Wuts, Protecting Groups
 10 in Organic Synthesis, 2nd. Ed., John Wiley & Sons, NY, 1991. Examples of carboxy protecting groups include C₁-C₆ alkyl groups such as methyl, ethyl, t-butyl and t-amyl; aryl(C₁-C₄)alkyl groups such as benzyl, 4-nitrobenzyl, 4-methoxybenzyl, 3,4-dimethoxybenzyl, 2,4-dimethoxybenzyl, 2,4,6-
 15 trimethoxybenzyl, 2,4,6-trimethylbenzyl, benzhydryl and trityl; silyl groups such as trimethylsilyl and t-butyldimethylsilyl; and allyl groups such as allyl and 1-(trimethylsilylmethyl)prop-1-en-3-yl.

Examples of amine protecting groups (PG) include acyl
 20 groups, such as groups of formula RCO in which R represents C₁₋₆ alkyl, C₃₋₁₀ cycloalkyl, phenyl C₁₋₆ alkyl, phenyl, C₁₋₆ alkoxy, phenyl C₁₋₆ alkoxy, or a C₃₋₁₀ cycloalkoxy, wherein a phenyl group may be optionally substituted, for example by one or two of halogen, C₁-C₄ alkyl and C₁-C₄ alkoxy.

25 Preferred amino protecting groups include benzyloxycarbonyl (CBz), t-butoxycarbonyl (Boc) and benzyl.

In another aspect the invention relates to a process for preparing a compound of formula I comprising deprotecting a compound of formula (I'):



Wherein R^{2'} is R² (as hereinabove defined) or protected R², Cy' is Cy (as hereinabove defined) or protected Cy and Lp(D)_n' is Lp(D)_n (as hereinabove defined) or protected Lp(D)_n; providing at least one protecting group is present.

35 If necessary physiologically tolerable salts can be formed using methods known in the art.

All novel intermediates described herein are provided as further aspects of the invention.

The compounds of the invention may be administered by any convenient route, e.g. into the gastrointestinal tract (e.g. rectally or orally), the nose, lungs, musculature or vasculature or transdermally. The compounds may be administered in any convenient administrative form, e.g. tablets, powders, capsules, solutions, dispersions, suspensions, syrups, sprays, suppositories, gels, emulsions, patches etc. Such compositions may contain components conventional in pharmaceutical preparations, e.g. diluents, carriers, pH modifiers, sweeteners, bulking agents, and further active agents. Preferably the compositions will be sterile and in a solution or suspension form suitable for injection or infusion. Such compositions form a further aspect of the invention.

The following are examples of pharmaceutical compositions of compounds according to the invention.

20

25

30

35

Formulation 1

Hard gelatin capsules are prepared using the following ingredients:

5	<hr/>	
		Quantity (mg/capsule)
10	<hr/>	
	Active Ingredient	250
	Starch, dried	200
	Magnesium stearate	<u>10</u>
15	Total	460 mg
	<hr/>	

The above ingredients are mixed and filled into hard gelatin capsules in 460 mg quantities.

Formulation 2

Tablets each containing 60 mg of active ingredient are made as follows:

5		
	Active Ingredient	60 mg
	Starch	45 mg
	Microcrystalline cellulose	35 mg
10	Polyvinylpyrrolidone	4 mg
	Sodium carboxymethyl starch	4.5 mg
	Magnesium stearate	0.5 mg
	Talc	<u>1 mg</u>
15	Total	150 mg

The active ingredient, starch, and cellulose are passed through a No. 45 mesh U.S. sieve and mixed thoroughly. The solution of polyvinylpyrrolidone is mixed with the resultant powders which are then passed through a No. 14 mesh U.S. sieve. The granules so produced are dried at 50°C and passed through a No. 18 mesh U.S. sieve. The sodium carboxymethyl starch, magnesium stearate, and talc, previously passed through a No. 60 mesh U.S. sieve, are then added to the granules which, after mixing, are compressed on a tablet machine to yield tablets each weighing 150 mg.

Viewed from this aspect the invention provides a pharmaceutical composition comprising a serine protease inhibitor according to the invention together with at least one pharmaceutically acceptable carrier or excipient. The pharmaceutical composition may also optionally comprise at least one further antithrombotic and/or thrombolytic agent.

Viewed from a further aspect the invention provides the use of a serine protease inhibitor according to the invention for the manufacture of a medicament for use in a method of

treatment of the human or non-human animal body (e.g. a mammalian, avian or reptilian body) to combat (i.e. treat or prevent) a condition responsive to said inhibitor.

Viewed from a further aspect the invention provides a
5 method of treatment of the human or non-human animal body
(e.g. a mammalian, avian or reptilian body) to combat a
condition responsive to a serine protease inhibitor (e.g. a
condition such as a thrombotic disorder responsive to a factor
Xa inhibitor), said method comprising administering to said
10 body an effective amount of a serine protease inhibitor
according to the invention.

The dosage of the inhibitor compound of the invention
will depend upon the nature and severity of the condition
being treated, the administration route and the size and
15 species of the patient. However in general, quantities of
from 0.01 to 100 $\mu\text{mol/kg}$ bodyweight will be administered.

All publications referred to herein are hereby
incorporated by reference.

The invention will now be described further with
20 reference to the following non-limiting Examples.

Experimental

Abbreviations used follow IUPAC-IUB nomenclature. Additional abbreviations are HPLC, high-performance liquid chromatography; rpHPLC, reverse phase HPLC; SCX, strong cation exchange resin; THF, tetrahydrofuran; HOAc, acetic acid; DMSO, dimethyl sulfoxide (perdeuterated if for NMR); EtOAc, ethyl acetate; EtOH, ethanol; DMF, dimethylformamide; DCM, dichloromethane; HAOT, 1-hydroxy-7-azabenzotriazole; HOBT, 1-hydroxy benzotriazole, EDCI, 1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride; DIPEA, diisopropylethylamine; Boc, tertiary butyloxycarbonyl; TEA, triethylamine; TFA, trifluoroacetic acid; MALDI-TOF, Matrix assisted laser desorption ionisation-time of flight mass spectrometry, CI-MS, chemical ionization mass spectrum; API-MS (atmospheric pressure chemical ionization mass spectra) were obtained on a PESCiex (trademark) API 150EX with a heated nebulizer and nitrogen as the reagent gas in positive ion mode. RT, retention time; TLC, thin layer chromatography with R_f as relative mobility. All solution concentrations are expressed as %Vol./%Vol. unless otherwise stated. Reagents were obtained from a variety of commercial sources.

IR means an infrared spectrum was obtained. ^1NMR , $^1\text{H-NMR}$, or $^1\text{H NMR}$ means a proton magnetic resonance spectrum was obtained.

In general in this specification, "D-" or "R-" in the name of a product indicates the product was made beginning with a chiral starting material, for example D-phenylglycine; however, racemization may have occurred, and the enantiomeric purity may not have been determined.

General Experimental Procedures:

Purification of Compounds (rpHPLC chromatography)
Material was purified using standard reverse-phase preparative chromatography techniques. A 5 micron, 20 x 50 mm O.D. C18 column was used (YMC ODS-A) with a flow rate of 20 mL/min and

an standard elution time of 10-15 minutes. A gradient of water:acetonitrile (between 95:5 to 5:95; each eluent w/0.1% TFA) over the elution time was used. Fractions containing product were concentrated, frozen, and lyophilized to afford, 5 when applicable, the trifluoroacetate salt of the product. The free base could be obtained, if desired, by loading a methanolic solution of the trifluoroacetate salt onto an ion-exchange resin (SCX, Varian) and subsequent elution of the resin with methanol followed by 2N ammonia in methanol.

10 Concentration of the later fractions afforded the free base product. Preparation of a hydrochloride salt from the free base was completed by treatment an organic solution of the free base (EtOAC, methylene chloride) with anhydrous HCl in diethyl ether and concentration.

15

Preparation of Starting Materials and Intermediates

Intermediate substituted glycine compounds for starting materials and intermediates, including those in which the 20 amino group and/or the carboxy group is protected, conveniently may be prepared using one of the procedures below, or by a similar procedure. It may be convenient or preferred to change the order of steps in the preparation of a compound of the invention and to use a similar procedure with 25 a different intermediate. In particular, it may be convenient to use an acyl group R_2 -CO- initially in a preparation, rather than an amino protecting group.

Abbreviations, in addition to others listed herein, include:

30 TEMPO: 2,2,6,6-tetramethyl-1-piperidinyloxy, free radical;
(DHQD)2PHAL: hydroquinidine 1,4-phthalazinediyl diether;
r.b., round bottomed;

Preparation of Intermediates KE-1 - KE-3

35 The following compounds were prepared according to the indicated method (Method KE-A) from the indicated starting materials, unless otherwise described.

Intermediate KE-1**Ethyl oxo-quinolin-8-yl-acetate.****Method KE-A**

To a stirring solution of 8-bromoquinoline (10.1 g, 48.5 mmol) in THF (500 mL) at -78 °C was added dropwise a 1.3 M solution of sec-butyl lithium (37.3 mL, 48.5 mmol) in cyclohexane. After 5 min, diethyl oxalate (8 mL, 58.3 mmol) was added; and the solution was allowed to slowly warm to room temperature overnight. The next morning, the reaction was quenched with the addition of saturated aqueous NH_4Cl ; and the solvent was removed in vacuo. The residue was partitioned between ethyl acetate and satd aq. NaHCO_3 ; the layers were separated; and then the aqueous phase was washed with brine, dried with MgSO_4 , filtered and concentrated in vacuo. The residue was chromatographed over silica gel, eluting with 20% ethyl acetate/hexanes through 25% ethyl acetate/hexanes. The product containing fractions were combined and concentrated in vacuo to give 5.88 g (53%) of the title compound.

20 $^1\text{H-NMR}$

IS-MS, m/e 230.1 (M+1)

Intermediate KE-2**Ethyl oxo-quinolin-5-yl-acetate.**

25 Prepared from 5-bromoquinoline and diethyl oxalate using Method KE-A.

 $^1\text{H-NMR}$

IS-MS, m/e 230.0 (M+1)

30

Intermediate KE-3**Ethyl oxo-thiazol-5-ylacetate.**

To a r.b. flask (500 cm³) under argon, fitted with ethanol thermometer, septum cap, and dropping funnel, was added anhydrous ether (100 cm³) with stirring. This was cooled to -78C and 2M n-butyllithium (60 cm³, 120 mmol) was added.

A solution of silyl thiazole (16g, 16cm³, 100 mmol) in

anhydrous ether (100 cm³) was then added by dropping funnel over 30 minutes. This was allowed to stir for 1 hour to give a peach suspension. To this, was added diethyl oxalate (16.3 cm³, 17.5g, 120 mmol) rapidly to give a brown solution,

5 resulting in a temperature increase to -30 °C. This was allowed to cool back to -78 °C and stirred for 30 minutes. Reaction monitored by ¹H NMR (CDCl₃).

The brown solution was poured onto 5% hydrochloric acid solution (300 cm³) with vigorous stirring for 30 minutes.

10 Ether layer was separated and washed with saturated bicarbonate (ca. 80 cm³), dried over magnesium sulphate, and concentrated *in vacuo* to give an orange oil. This was purified by flash chromatography (10% ethyl acetate/hexane) to give a yellow oil (7.31g, 39.47 mmol) [40% Yield].

15

¹H NMR (CDCl₃); 1.42 (3H, t), 4.45 (2H, q), 8.89 (1H, s), 9.10 (1H, s).

Preparation of Intermediates OX-1 - OX-7

20 The following compounds were prepared according to the indicated method (Method OX-A or Method OX-B) from the indicated starting materials unless otherwise described.

Intermediate OX-1

25 Ethyl Hydroxyimino-pyridin-2-yl-acetate.

Method OX-A

To a stirring solution of ethyl 2-pyridylacetate (12.6 g, 76.3 mmol) in acetic acid (19 mL) at 5 °C was added a solution of sodium nitrite (6.05 g, 87.7 mmol) in water (12 mL) at a rate
30 sufficient to maintain the internal temperature below 15 °C. After complete addition and an additional 30 min, an additional 30 mL of water were added. The resulting white precipitate was filtered, washed with water, satd aq. NaHCO₃, and again with water. The solid was then dried under vacuum to give 14.1 g
35 (95%) of the title compound.

¹H-NMR

IS-MS, m/e 194.9 (M+1)

Analysis for $C_9H_{10}N_2O_3$:

Calcd: C, 55.67; H, 5.19; N, 14.43;

Found: C, 55.79; H, 5.14; N, 14.13.

5

Intermediate OX-2

Ethyl Hydroxyimino-pyridin-3-yl-acetate.

Using the procedure of Tikk et al [Acta. Chimica, Hungarica, 114(3-4), 355], a mixture of ethyl hydroxyimino-pyridin-3-yl-acetate and n-butyl hydroxyimino-pyridin-3-yl-acetate was prepared from ethyl 3-pyridinyl-acetate and n-butyl nitrite.

1H -NMR

15 IS-MS, m/e 195 (M+1), 223.1 (M+1)

Intermediate OX-3

Ethyl Hydroxyimino-quinolin-8-yl-acetate.

Method OX-B

20 To a stirring solution of ethyl oxo-quinolin-8-yl-acetate (5.5 g, 24 mmol) in ethanol (140 mL) was added sodium acetate (2.16 g, 26.4 mmol) followed by hydroxylamine hydrochloride (2.67 g, 38.4 mmol). The mixture was heated to reflux; and, after 7 h, the heating mantle was removed and the solution was
25 allowed to stir overnight at room temperature. The next morning, the solvent was removed in vacuo and the residue was partitioned between ethyl acetate and satd aq. $NaHCO_3$. The layers were separated and the organic phase was washed with brine, dried with Na_2SO_4 , filtered and concentrated in vacuo.
30 The resulting foam was recrystallized from dichloromethane/hexanes to give an initial crop of 2.5 g of the title compound as an off-white solid, followed by 0.31 g of a second crop. The mother liquor was then concentrated in vacuo, the residue was dissolved in a minimal amount of
35 dichloromethane. The solution was then chromatographed over silica gel, eluting with 30% ethyl acetate/hexanes, then 40% ethyl acetate/hexanes, and finally with ethyl acetate. The product containing fractions were combined and concentrated in

vacuo to give 1.94 g of the title compound for a combined yield of 4.75 g (81%).

¹H-NMR

5 IS-MS, m/e 245.0 (M+1)

Intermediate OX-4

Ethyl Hydroxyimino-quinolin-5-yl-acetate.

Prepared from ethyl oxo-quinolin-5-yl-acetate using

10 Method OX-B.

¹H-NMR

IS-MS, m/e 245.0 (M+1)

15 Intermediate OX-5

Ethyl Hydroxyimino-thiazol-5-ylacetate.

To a r.b. flask (500 cm³) was added the ethyl oxo-thiazol-5-ylacetate (6.30g, 34.02 mmol) to ethanol (ca. 180 cm³) with stirring. Sodium acetate (3.06g, 37.30 mmol) and
20 hydroxylamine hydrochloride (3.78g, 54.43 mmol) were then added to give an off-white suspension. This was brought to reflux at 85C for 1 hour. Reaction monitored by TLC (60% hexane/ethyl acetate; s.m. r.f 0.5, prod. r.f. 0.3.).
Reaction cooled and concentrated in vacuo. Product taken up

25 in ethyl acetate (c.a. 200 cm³) and washed with 5% hydrochloric acid solution. Ethyl acetate layer was dried over magnesium sulphate and evaporated to dryness to give a cream solid (6.372g, 31.825 mmol) [94% Yield].

30 ¹H NMR (CDCl₃); 1.40 (3H, m), 4.40 (2H, m), 8.06 (1/3H, s), 8.78 (1/3H, s), 8.95 (2/3H, s), 8.98 (2/3H, s).

Intermediate OX-6

Ethyl α-Oximino-thiazole-4-acetate.

35 To a 2 necked r.b. flask (100 cm³) with ethanol thermometer, concentrated sulphuric acid (25 cm³) was added

and cooled to 0 °C with stirring. To this solution was added the ethyl- α -oximino-2-aminothiazole-4-acetate (5.00g, 23.231 mmol). Water (10 cm³) was then added and cooled to -10 °C. A solution of sodium nitrite (1.683g, 24.393 mmol) in water (5 cm³) was then added slowly over an hour keeping the temperature below -5°C.

To a separate r.b. flask (500 cm³), water (180 cm³) was added and cooled to 3°C. The reaction solution was poured in to the cold water with stirring and then cooled to -5°C. To this solution, 50% hypophosphoric acid (90 cm³) was added dropwise over 10 minutes keeping the temperature at -5 °C. The solution was allowed to warm to room temperature and stirred overnight. The product was extracted with diethyl ether (ca. 3x150 cm³) and washed with water. The ether layer was concentrated in vacuo and treated to flash chromatography (50% ethyl acetate/n-hexane) to yield a orange oil upon concentration in vacuo (0.60g, 3.00 mmol) [13% yield].

¹H NMR (CDCl₃) 1.35 (3H, m), 4.35 (2H, m), 8.4 (1H, s), 8.9 (1H, s), 14.4 (1H, s).

Intermediate OX-7

Ethyl α -Oximino-2-methylthiazole-4-acetate.

This was prepared from ethyl- γ -chloro- α -oximino-acetoacetate (1.44g) using the method of Hatanaka et al. (*Journal of Medicinal Chemistry*, 1973, 16(9), 978-984) to yield the titled compound (0.64g).

¹H NMR (CDCl₃) 1.35 (3H, t), 2.7 (3H, s), 4.35 (2H, q), 8.2 (1H, s).

Ethyl γ -Chloro- α -oximinoacetoacetate.

This was prepared from ethyl oximinoacetoacetate (1.73g) using the method of Hatanaka et al. (*Journal of Medicinal Chemistry*, 1973, 16(9), 978-984) to yield the titled compound

(1.44g).

¹H NMR (CDCl₃) 1.25 (3H, t), 4.3 (2H, q), 4.55 (2H, s), 9.45 (1H, s), contains 20% starting material by NMR.

5

Ethyl Oximinoacetoacetate

This was prepared from ethyl acetoacetate (10.00g) using the method of Fischer (*Organic Synthesis Coll.* Vol. 3, 513-516) to yield the titled compound (12.45g).

10

¹H NMR (CDCl₃) 1.25 (3H, t), 2.35 (3H, s), 4.3 (2H, q), 8.8 (1H, br.).

Preparation of Intermediates AL-1 - AL-3

15 The following compounds were prepared according to the indicated method (Method AL-A or Method AL-B) from the indicated starting materials, unless otherwise described.

Intermediate AL-1

20 R-3-Bromo-(1-*t*-butoxycarbonylamino-2-hydroxyethyl)benzene.

Method AL-A

Sodium hydroxide (3.33 g, 83.25 mmol) was dissolved in water (220 mL), and 20 mL of the resulting solution was removed and added to potassium osmate (410 mg, 1.11 mmol).

25 The remaining sodium hydroxide solution (200 mL) was added to a stirred solution of *t*-butyl carbamate (9.9 g, 84.5 mmol) in *n*-propanol (110 mL) followed by freshly prepared *t*-butyl hypochlorite (9.65 mL; 83.5 mmol). After stirring for 5 min, the solution was cooled to 0 °C. A solution of (DHQD)₂PHAL
30 (1.30 g, 1.67 mmol) in *n*-propanol (110 mL) was added, followed by a solution of 3-bromostyrene (5 g, 27.31 mmol) in *n*-propanol (220 mL), followed by dropwise addition of the potassium osmate/sodium hydroxide solution. The reaction was stirred overnight. Saturated aqueous sodium sulfite (150 mL)
35 was added, and the reaction was stirred for 15 min. The aqueous layer was separated and extracted with ethyl acetate

(3x 200 mL). The combined organic layers were washed with brine and dried over MgSO_4 . Removal of solvent under vacuum gave the crude product which was purified by chromatography (silica, 3:2 hexane:ethyl acetate then rechromatographed loading with toluene, gradient elution with hexane - 4:1 hexane:ethyl acetate) to give the title product (4.18 g, 49%).

Melting Point = 90-91 °C

^1H NMR (CDCl_3).

10

Intermediate AL-2

R-3-Methoxycarbonyl-(1-t-butoxycarbonylamino-2-hydroxy-ethyl)benzene.

Method AL-B

15 In a glass liner containing a stirrer bar was placed $\text{Pd}(\text{OAc})_2$ (871 mg, 3.88 mmol), PPh_3 (1.96 g, 7.47 mmol, NaOAc (1.48 g, 18.04 mmol) and DMF (82 mL). To this stirred solution was added a solution of R-3-bromo-(1-t-butoxycarbonylamino-2-hydroxyethyl)benzene (4.27 g, 13.5 mmol) in
20 MeOH (82 mL). The resulting solution was purged with nitrogen and placed in a stirred pressure vessel. The system was charged to 4.1 bar (60 psig) of CO and heated at 95 °C for 36 h. The mixture was cooled to room temperature, filtered through diatomaceous earth, and partitioned between ethyl
25 acetate and water. The organic layer was washed with water (3x) and brine (1x) and dried over MgSO_4 . Removal of solvent under vacuum gave the crude product which was purified by chromatography (silica gel, gradient elution with 30-35% ethyl acetate/hexane) to provide the title product (3.53 g, 89%).

30

Melting Point = 73-75 °C with decomposition

^1H NMR (CDCl_3).

API-MS, m/e = 240 (M-C₄H₉+1).

5 Intermediate AL-3

R-3-Cyano-(1-t-butoxycarbonylamino-2-hydroxyethyl)benzene.

Prepared from 3-cyanostyrene using Method AL-A.

3-Cyanostyrene was prepared using the method described below.

10 Melting Point = 76 °C.

¹H NMR (CDCl₃).

Preparation of 3-Cyanostyrene

To a stirred suspension of methyltriphenylphosphonium
15 bromide (75 g, 209.71 mmol) in dry THF (750 mL) at 0 °C under
nitrogen was added dropwise n-BuLi (83 mL, 2.5 M in hexanes,
207.50 mmol). The mixture was warmed to room temperature. 3-
Cyanobenzaldehyde (25 g, 190.65 mmol) was added as a solid in
5 g batches, and the mixture was stirred at room temperature
20 overnight. The reaction was quenched in water, and the
solvent was removed under vacuum. The residue was dissolved
in the minimal amount of THF, and triphenylphosphine oxide was
precipitated using ether. The solid was filtered through
diatomaceous earth, and the filtrate was concentrated.
25 Distillation by Kugelrohr at 90 °C/33 Pa (0.25 mm Hg) gave the
product as a colorless oil (15.5 g, 62%).

Boiling Point = 90 °C at 0.25 mmHg.

¹H NMR (CDCl₃).

30

Preparation of Intermediates PAE-1 - PAE-16

The following compounds were prepared according to the
indicated method (Method PAE-A, Method PAE-B, Method PAE-C,
Method PAE-D or PAE-E) from the indicated starting materials,

unless otherwise described.

Intermediate PAE-1

Boc-D,L-(2-pyridinyl)glycine Ethyl Ester.

5 Method PAE-A

To a solution of ethyl hydroxyimino-pyridin-2-yl-acetate (7.8 g, 40.15 g) in ethanol (175 mL) and glacial acetic acid (20 mL) was added 5% Pd/C, and the mixture was shaken in a hydrogenation apparatus under an atmosphere of hydrogen at 4.1 bar (45 psig) for 4 h. The mixture was filtered through diatomaceous earth and concentrated in vacuo. The residue was dissolved in THF/H₂O (1/1, 240 mL) and treated with di-tert-butyl dicarbonate (14.23 g, 65.2 mmol) and sodium bicarbonate (27.4 g, 326 mmol). After stirring at room temperature for 2 h, the solution was concentrated in vacuo and the residue was partitioned between EtOAc and water. The organic phase was washed with brine, dried over magnesium sulfate, filtered and concentrated in vacuo. The crude material was purified via chromatography over silica gel, eluting with a stepwise gradient of 10-20% ethyl acetate in dichloromethane to give 8.11 g (72%) of the title compound as a yellow oil.

¹H-NMR

IS-MS, m/e 281.1 (M+1)

25

Intermediate PAE-2

Boc-D,L-(3-pyridinyl)glycine Ethyl Ester.

Prepared from ethyl hydroxyimino-pyridin-3-yl-acetate using Method PAE-A.

30

¹H-NMR

IS-MS, m/e 281.1 (M+1)

Intermediate PAE-3

35 Boc-D,L-(8-quinolinyl)glycine Ethyl Ester.

Method PAE-B

To a stirring solution of ethyl hydroxyimino-quinolin-8-yl-acetate (2.4 g, 9.8 mmol) in 50% aq. formic acid (50 mL) at 0 °C

was added zinc dust (2 g, 31 mmol). After 1 min, the mixture was filtered through diatomaceous earth and the filtrate was loaded onto an SCX column. After washing the column with methanol, the product was eluted with a 3 to 1 mixture of 5 dichloromethane and (2 N NH₃ in methanol). The product containing fractions were combined and concentrated in vacuo to give 2.24 g of light orange oil (IS-MS, m/e 231.0 (M+1)).

The oil (2.14 g, 9.3 mmol) was dissolved in THF (40 mL) and to this stirring solution was added triethylamine (1.4 mL, 10.2 10 mmol), followed by di-tert-butyl-dicarbonate (2.1 g, 9.8 mmol).

After 45 min, the solvent was removed in vacuo and the residue was partitioned between ethyl acetate and water. The organic phase was then washed with satd aq. NaHCO₃, dried with Na₂SO₄, filtered and concentrated in vacuo. The residue was dissolved 15 in a minimum volume of dichloromethane and chromatographed over silica gel, eluting with 5% ethyl acetate in hexanes. The product containing fractions were combined and concentrated to give 2.5 g (81%) of the title compound.

20 1H-NMR

IS-MS, m/e 331.0 (M+1)

Intermediate PAE-4

Boc-D,L-(5-quinolinyl)glycine Ethyl Ester

25 Prepared from ethyl hydroxyimino-quinolin-5-yl-acetate using Method PAE-B.

1H-NMR

IS-MS, m/e 331.0 (M+1)

30

Intermediate PAE-5

N-4-Methoxybenzoyl-N-2,4-dimethoxybenzyl-D,L-(2-trifluoromethylphenyl)glycine Methyl Ester.

Method PAE-C

35 To 2-trifluoromethylbenzaldehyde (1 g, 5.7 mmol) with stirring was added 2,4-dimethoxybenzylamine (0.86 mL, 5.7 mmol) and methanol (2 mL). After 5 min, the solution was diluted with toluene 100 mL and concentrated in vacuo (twice). The residue

was then dissolved in anhydrous methanol (12 mL) and 1,1-dimethyl-2-(methoxycarbonyloxy)ethyl isonitrile [Tetrahedron, 55 (1999) 7411-7420] (0.9 g, 5.7 mmol) was added, followed by 4-methoxybenzoic acid (0.87 g, 5.7 mmol). After stirring for 72 h, the solvent was removed in vacuo and the residue was chromatographed over silica gel, eluting with a step gradient of 30% ethyl acetate in hexanes through 50% ethyl acetate in hexanes. The product containing fractions were combined and concentrated in vacuo; and then the residue was dissolved in ethyl acetate, washed with satd aq. NaHCO_3 , dried with Na_2SO_4 , filtered and concentrated to give 1.76 g (48%) of thick oil (NMR, IS-MS, m/e 633.0 (M+1)).

The oil (0.5 g, 0.79 mmol) was then dissolved in toluene (5 mL) and concentrated in vacuo (twice) to give a white foam. The residue was then dissolved in THF (3 mL) and potassium tert-butoxide (0.11 g, 0.95 mmol) was added. After 15 min, 12 N HCl (0.079 mL, 0.95 mmol) was added and the solution was allowed to stand overnight in the refrigerator. The next morning, the solvent was removed and the residue was chromatographed over silica gel, eluting with 30% ethyl acetate in hexanes. The product containing fractions were combined and concentrated to give 0.32 g (79%) of the title compound.

¹H-NMR

IS-MS, m/e 518.0 (M+1)

Intermediate PAE-6

BOC-D,L-(5-thiazolyl)glycine ethyl ester.

To a r.b. flask (250 cm³), D,L-(5-thiazolyl)glycine ethyl ester (4.60g, 24.7 mmol) was added to tetrahydrofuran (c.a. 100 cm³) with stirring to give a yellow solution. BOC anhydride (5.439g, 24.948 mmol) and triethyl amine (3.79 cm³, 2.75g, 27.17 mmol) were then added with stirring for 1 hour. Reaction monitored by TLC (60% hexane/ethyl acetate; s.m. r.f 0.05, prod. r.f. 0.5.). The reaction concentrated in vacuo and product taken up in ethyl acetate (c.a. 150 cm³), washed with 5% hydrochloric acid solution (c.a. 30 cm³), and saturated

bicarbonate (ca. 30cm³). Ethyl acetate layer was dried over magnesium sulphate and evaporated to dryness to give an orange oil (7.42g, ~24.70 mmol) [~100% Yield].

5 ¹H NMR (CDCl₃); 1.30 (3H, t), 1.48 (9H, s), 4.28 (2H, q), 5.68 (1H, br.), 7.88 (1H, s), 8.78 (1H, s).

D,L-(5-Thiazolyl)glycine Ethyl Ester.

To a r.b. flask (250 cm³), was added 5-thiazolyl-
10 oximinoacetic acid ethyl ester (6.37g, 31.825 mmol) to ethanol (c.a. 80cm³) with stirring. 50% Formic acid solution (50 cm³) was added with zinc dust (5.10g, 81.83 mmol) and allowed to stir overnight. Reaction monitored by TLC (60% hexane/ethyl acetate; s.m. r.f 0.3, prod. r.f. 0.05.).
15 Reaction solution filtered over celite and filtrate concentrated in vacuo. This was basified to pH 9 with anhydrous potassium carbonate and product taken up in 3:1 chloroform/isopropanol solution (c.a. 200 cm³). This was washed with saturated bicarbonate (c.a. 50 cm³), dried over
20 magnesium sulphate and concentrated in vacuo to give a brown oil (4.60g, 24.70 mmol) [78% Yield].

¹H NMR (CDCl₃); 1.25 (3H, t), 1.95 (2H, br.), 4.22 (2H, q), 4.85 (1H, s), 7.80 (1H, s), 8.70 (1H, s).

25

Intermediate PAE-7

N-Boc-D,L-(4-thiazolyl)glycine ethyl ester

To a solution of D,L-(4-thiazolyl)glycine ethyl ester (0.460g, 2.470 mmol) in tetrahydrofuran (20 cm³), was added di-
30 tert-butyl dicarbonate (0.530g, 2.470 mmol) and triethylamine (0.344 cm³, 2.470 mmol). This was allowed to stir for 1 hour and the solution concentrated in vacuo. The oil was taken up in ethyl acetate (c.a. 50 cm³) washed with 0.5% hydrochloric acid solution (c.a. 20 cm³), and saturated sodium bicarbonate
35 solution (c.a. 20 cm³). This was then dried over magnesium sulphate and concentrated in vacuo to yield an orange oil

(0.709g, 2.477 mmol) [~100% yield].

¹H NMR (CDCl₃) 1.15 (3H, t), 1.35 (9H, s), 4.1 (2H, m), 5.45 (1H, d), 5.75 (1H, d), 7.3 (1H, d), 8.7 (1H, d).

5

D,L-(4-Thiazolyl)glycine Ethyl Ester.

This was prepared from ethyl- α -oximino-thiazole-4-acetate (0.60g) using the method of Hatanaka et al. (*Journal of Medicinal Chemistry*, 1973, 16(9), 978-984) to yield the titled
10 compound (0.46g).

¹H NMR (CDCl₃) 1.25 (3H, t), 1.8-2.3 (2H, br.), 4.1 (2H, m), 4.75 (1H, s), 7.25 (1H, d), 8.7 (1H, d).

15 Intermediate PAE-8

N-Boc-D,L-(2-methylthiazol-4-yl)glycine Ethyl Ester

To a solution of D,L-(2-methylthiazol-4-yl)glycine ethyl ester (0.397g, 1.982 mmol) in tetrahydrofuran (20 cm³), was added di-tert-butylidicarbonate (0.475g, 2.180 mmol) and
20 triethylamine (0.304 cm³, 2.180 mmol). This was allowed to stir for 1 hour and the solution concentrated in vacuo. The oil was taken up in ethyl acetate (c.a. 50 cm³) washed with 0.5% hydrochloric acid solution (c.a. 20 cm³), and saturated sodium bicarbonate solution (c.a. 20 cm³). This was then dried over
25 magnesium sulphate and concentrated in vacuo to yield a yellow oil (0.654g, 2.177 mmol) [~100% yield].

¹H NMR (CDCl₃) 1.1 (3H, s), 1.35 (9H, s), 2.6 (3H, s), 4.15 (3H, m), 5.3 (1H, d), 5.7 (1H, s), 7.0 (1H, s).

30

D,L-(2-Methylthiazol-4-yl)glycine Ethyl Ester.

This was prepared from ethyl- α -oximino-2-methylthiazole-4-acetate (0.62g) using the method of Hatanaka et al. (*Journal of Medicinal Chemistry*, 1973, 16(9), 978-984) to yield the
35 titled compound (0.40g).

^1H NMR (CDCl_3) 1.15 (3H, t), 1.95 (2H, br.), 2.6 (3H, s), 4.15 (2H, m), 4.65 (1H, s), 6.95 (1H, s).

Intermediate PAE-9

5 Boc-R-(4-Hydroxyphenyl)glycine methyl ester

To a stirred mixture of R-(4-hydroxyphenyl)glycine methyl ester hydrochloride (14g) and sodium bicarbonate (11.7g) in THF (150ml) and water (50ml), was added in one portion, di- t-butyl dicarbonate (15.9g). The mixture was stirred rapidly to allow thorough mixing for 4h. Hexane (75ml) was added and the organic layer separated and washed with sat. sodium bicarbonate solution, then brine and then dried with magnesium sulphate. The drying agents was filtered off and washed with a little THF and evaporated to dryness, finishing with a high vacuum pump to remove the last traces of di- t-butyl dicarbonate. Yield 19.7g, 96%.

^1H NMR

20 R-(4-Hydroxyphenyl)glycine Methyl Ester Hydrochloride.

To a dry 250ml three necked round bottom flask, equipped with a low temperature thermometer, a septum for nitrogen coverage and another for introduction of thionyl chloride by syringe, was added R-4-hydroxyphenylglycine (12.5g) and dry methanol (24ml). The mixture was stirred (magnetic stirrer) and cooled to an internal temperature of -20°C using cardice/acetone. Using a syringe, thionyl chloride was added dropwise to the cooled mixture over a period of 10min. (Care: the reaction of thionyl chloride with methanol is very exothermic and rate of addition should be such that the thionyl chloride is efficiently stirred into the mixture and that the temperature does not rise above -20°C . Once the addition was complete the mixture was allowed to warm to room temperature overnight (16-18hr). Dry ether (150ml) was added and the white ppt. that formed was filtered off, washed with a little more ether and dried. Yield 15.5g 95%.

^1H NMR

Intermediate PAE-10**Boc-R-(4-Trifluoromethanesulphonyloxyphenyl)glycine Methyl Ester Hydrochloride**

5 To a stirred solution of Boc-R-(4-hydroxyphenyl)glycine methyl ester 19g in dichloromethane 400ml was added 2,6-lutidine 9.44ml and 4-dimethylaminopyridine 1.65g and the mixture cooled in an ice bath. Trifluoromethanesulphonic anhydride 13.74ml was added over a period of 5min and then the
10 reaction left to warm to room temperature over 4h. The organic solution was washed with water, 2 x 150ml, 1N HCl 2 x 150ml and the saturated sodium bicarbonate 150ml. The organics were dried with magnesium sulphate and then evaporated to an oil. The mixture was purified using flash
15 chromatography (SiO₂ 250g eluting with 1:1 hexane/dichloromethane and then neat dichloromethane). Pure product fractions were combined and evaporated, finishing with a high vacuum pump to remove all traces of solvent, to give a white solid, 19g 77%.

20

¹H NMR**Intermediate PAE-11****Boc-R-(4-Methoxycarbonylphenyl)glycine Methyl Ester.****25 Method PAE-D**

Boc-R-4-trifluoromethanesulphonyloxyphenylglycine methyl ester (15g), methanol (32.6ml), bis-1,3-diphenylphosphinylpropane (448mg), palladium (II) acetate (255mg), triethylamine (10.2ml) and dimethylformamide (72ml) were
30 placed in the glass liner of the Parr reactor and the reactor assembled. The vessel was pressurised to ~10psi with nitrogen and the gas released (repeated five times to remove all oxygen from the system). Carbon monoxide gas was then carefully introduced (use extreme care -the gas cylinder is pressurised
35 to far beyond the bursting disc pressure of the Parr, ideally use a pressure regulator to reduce the pressure to ~100psi) to ~20psi and released three times (into the back of a fume

hood). Carbon monoxide was then added to ~100psi and the stirrer started. The vessel was slowly heated to 65°C internal temperature and then stirred at 65°C overnight. (At the early stages more carbon monoxide was added to maintain ~100psi) A
5 sample was removed after 18h and examined by tlc. When complete, the reaction was cooled to ~30°C, the gas released and the vessel flushed five times with nitrogen as before. The reaction mixture was partitioned between ethyl acetate and water and the organic layer washed with 1M hydrochloric acid
10 and then saturated sodium bicarbonate. The solution was dried with MgSO₄ and evaporated. Flash chromatography of the resulting oil gave the product, pure by tlc, 10.6g 90%.

¹H NMR

15

Intermediate PAE-12

Boc-R-(4-Benzyloxycarbonylphenyl)glycine Methyl Ester

Prepared from Boc-R-4-trifluoromethanesulphonyloxy phenylglycine methyl ester and benzyl alcohol using Method
20 PAE-D.

¹H NMR

Intermediate PAE-13

25 Boc-R-(4-Carboxyphenyl)glycine Methyl Ester.

Boc-R-(4-benzyloxycarbonylphenyl)glycine methyl ester (500mg) was dissolved in THF containing Pd/C 10% (100mg) and hydrogenated at 1atm for 2h. Removal of the catalyst by filtration and evaporation of solvent gave Boc-R-(4-carboxy-
30 phenyl)glycine methyl ester (330mg, 87%).

¹H NMR

Intermediat PAE-14

35 Boc-R-(4-carboxamidophenyl)glycine Methyl Ester.

Method PAE-E

To a solution of Boc-R-(4-carboxyphenyl)glycine methyl

ester (3.5g) in DMF 30ml was added EDCI (2.60g 1.36 mmol) and HOBT (1.4g 10.4mmol) and the mixture stirred for 10min before cooling in a ice bath and bubbling in ammonia gas for 5min. The mixture was stirred for 2h at room temperature and then
5 diluted with ethyl acetate and washed with water. The aqueous solution was extracted with a little ethyl acetate and the combined organics washed with brine. The organic solution was evaporated to an oil which was purified by flash
10 chromatography (SiO₂ - dichloromethane/ ethyl acetate 0 - 25%) to give Boc-R-(4-carboxamidophenyl)glycine methyl ester (1.7g 48%).

¹H NMR

15 **Intermediate PAE-15**

Boc-R-(4-methylcarboxamidophenyl)glycine Methyl Ester.

Prepared from Boc-R-(4-carboxyphenyl)glycine methyl ester and methylamine using Method PAE-E.

20 ¹H NMR

Intermediate PAE-16 (pb0-h5u-119, px099940)

N-4-Methoxybenzoyl-N-2,4-dimethoxybenzyl-D,L-(quinolin-4-yl)glycine Methyl Ester.

25 Prepared from quinoline-4-carboxaldehyde using Method PAE-C.

¹H NMR

30 **Preparation of Intermediates PAA-1 - PAA-20**

The following compounds were prepared according to the indicated method (Method PAA-A, Method PAA-B, Method PAA-C, Method PAA-D, or Method PAA-E) from the indicated starting materials, unless otherwise described.

35

Intermediat PAA-1

Boc-D,L-(2-chlorophenyl)glycine.

Method PAA-A

2-Chlorobenzaldehyde (20 mmol, 2.252 mL) and 2,4-dimethoxybenzylamine (20 mmol, 3.004 mL) were added together and stirred for 2 hours. DCM (5ml) was added and any water
5 separated and removed. tert-Butyl isonitrile (20 mmol, 2.262 mL) was added and stirred for 10mins followed by acetic acid (20 mmol, 1.145 mL). Stirring was continued for 3 days. The reaction mixture was then treated with TFA (30ml) and triethylsilane (5ml). After 3 hours the mixture was evaporated
10 to dryness, 6M HCl (100ml) added and the whole refluxed overnight at 130°C, stirring rapidly. The mixture was allowed to cool and extracted with EtOAc (50ml x2) the aqueous fraction was evaporated to dryness and treated with 2M NaOH solution. The mixture was extracted with EtOAc (50ml x2)
15 excess boc anhydride (5.2g) in dioxane (20ml) was added to the aqueous fraction and stirred overnight. The mixture was extracted with diethyl ether (100ml x2) acidified to pH 1 (CHCl₃) and extracted with EtOAc (50ml x2). The combined organic fractions were washed with water and evaporated to
20 dryness under high vacuo The product Boc -2-chlorophenyl-glycine (4.252g, 74.5%)

¹H nmr (CD₃CN/D₂O) 7.3 (4H, m); 5.5 (1H, s); 1.3 (9H, s). MS
286 (M+1)

25

Intermediate PAA-1'

(R)-Benzyloxycarbonyl-(2-chlorophenyl)glycine.

Prepared from 2-chlorostyrene using the method of Sharpless et al J.A.C.S. (1998) Vol120 No.6 1207-1217.

30

Intermediate PAA-2

Boc-D,L-(3-fluorophenyl)glycine.

Prepared from 3-fluorobenzaldehyde using Method PAA-A.

35 ¹H nmr (CD₃CN/D₂O) 7.3 (1H, m), 7.1 (3H, m); 5.2 (1H, s); 1.3 (9H, s). MS 270 (M+1)

Intermediate PAA-3**Boc-D,L-(4-fluorophenyl)glycine.**

Prepared from 4-fluorobenzaldehyde using Method PAA-A.

- 5 ^1H nmr ($\text{CD}_3\text{CN}/\text{D}_2\text{O}$) 7.3 (2H, m); 6.9 (2H, m), 5.0 (1H, s); 1.3 (9H, s). MS 270 (M+1)

Intermediate PAA-4**Boc-D,L-(2-methylphenyl)glycine.**

- 10 Prepared from 2-methylbenzaldehyde using Method PAA-A.

^1H nmr ($\text{CD}_3\text{CN}/\text{D}_2\text{O}$) 7.3 (4H, m); 5.5 (1H, s); 2.5 (3H, s); 1.3 (9H, s). MS 266 (M+1)

15 Intermediate PAA-5**Boc-D,L-(3-thienyl)glycine.**

Prepared from 3-thiophenecarboxaldehyde using Method PAA-A.

- 20 ^1H nmr ($\text{CD}_3\text{CN}/\text{D}_2\text{O}$) 7.5 (2H, m); 7.1 (1H, d); 5.3 (1H, s); 1.3 (9H, s). MS 258 (M+1)

Intermediate PAA-6**Boc-D,L-(2-fluorophenyl)glycine.**

- 25 Was obtained by treating D,L-2-fluorophenylglycine (Aldrich) with Boc anhydride (1.1eq) and 2M NaOH (1eq) in Ethanol. Aqueous work up as described above yielded the protected amino acid.

- 30 ^1H NMR

Intermediate PAA-7**Boc-D,L-(2-methoxyphenyl)glycine.**

Prepared from 2-methoxybenzaldehyde using Method PAA-A.

- 35 ^1H NMR

Intermediate PAA-8**Boc-D,L-(2-trifluoromethyl)phenylglycine.**

Prepared from 2-trifluoromethylbenzaldehyde using Method PAA-A.

5

¹H NMR**Intermediate PAA-9****Boc-D,L-(8-quinolinyl)glycine.**

10

Method PAA-B

To a stirring solution of Boc-D,L-(8-quinolinyl)glycine ethyl ester (2.29 g, 6.93 mmol) in 1,4-dioxane (11 mL) was added a solution of LiOH hydrate (0.32 g, 7.6 mmol) in water. After 2 h, the solvents were removed in vacuo and the residue was dissolved in water and washed with diethyl ether. The aqueous phase was then acidified to pH 3 with solid citric acid and extracted with ethyl acetate. The organic phase was then washed with brine, dried with Na₂SO₄, filtered and concentrated to give 2.06 g (98%) of the title compound.

20

¹H-NMR

IS-MS, m/e 303.0 (M+1)

Intermediate PAA-10**25 Boc-D,L-(5-quinolinyl)glycine.**

Prepared from Boc-D,L-(5-quinolinyl)glycine ethyl ester using Method PAA-B.

¹H-NMR

30 IS-MS, m/e 303.0 (M+1)

Intermediate PAA-11**Boc-D-(3-bromophenyl)glycine.**

Prepared from R-3-bromo-(1-t-butoxycarbonylamino-2-hydroxyethyl)benzene using Method PAA-C.

Melting Point = 130-132 °C with decomposition

¹H NMR (CDCl₃)

API-MS, $m/e = 286$ ($M-CO_2H+1$)

Intermediate PAA-12

Boc-D-(3-methoxycarbonylphenyl)glycine.

5 Method PAA-C

To a stirred solution of R-3-methoxycarbonyl-(1-t-butoxycarbonylamino-2-hydroxyethyl)benzene (338 mg, 1.14 mmol) in acetone (7.2 mL) was added 5% $NaHCO_3$ (3 mL). The reaction mixture was cooled to 0 °C. To the stirred suspension was
10 added KBr (14 mg, 0.12 mmol), TEMPO (181 mg, 1.16 mmol) and NaOCl dropwise (2.81 mL, 5.25%). After 1 h at 0 °C, TEMPO (136 mg, 0.88 mmol) and NaOCl (1.09 mL; 5.25%) were added. The reaction was stirred for a further 0.5 h at 0 °C and 5% $NaHCO_3$ (4.3 mL) was added. The reaction was allowed to warm to room
15 temperature overnight. Acetone was removed under vacuum and the crude product was partitioned between ethyl acetate and water. The aqueous layer was washed with ethyl acetate (2x) and acidified to pH 5 with 10% citric acid and extracted with ethyl acetate (4x). The combined organic extracts were dried
20 over $MgSO_4$. Removal of solvent under vacuum gave the product (305 mg, 86%).

1H NMR ($CDCl_3$)

API-MS, $m/e = 254$ ($M-C_4H_9+1$)

25

Intermediate PAA-13

Boc-D-(3-cyanophenyl)glycine.

Prepared from R-3-cyano-(1-t-butoxycarbonylamino-2-hydroxyethyl)benzene using Method PAA-C.

30

1H NMR ($CDCl_3$)

API-MS, $m/e = 221$ ($M-C_4H_9+1$)

Intermediate PAA-14

35 B c-D-(3-ethanesulfonylamino-phenyl)glycine.

To a stirring solution of 3--(ethanesulfonylamino-phenyl)glycine (20 g, 77.43 mmol) and sodium carbonate (8.2 g,

77.43 mmol) in 3:1 THF:water (200 mL) at 0 °C, was added di-tert-butyl dicarbonate (18.5 g, 85.17 mmol). After stirring for 30 min, the cold bath was removed; and after an additional 30 min at room temperature the solvent was removed; and the residue
5 was partitioned between ethyl acetate and water. The aqueous layer was acidified to pH 2 with KHSO₄ and extracted twice with ethyl acetate. The combined ethyl acetate extracts were washed with water, dried with Na₂SO₄, filtered and concentrated in vacuo to give 17.51 g (63%) of a white solid.

10

¹H-NMR

IS-MS, m/e 357.0 (M-1)

Intermediate PAA-15**15 N-Boc-D,L-(5-thiazolyl)glycine.**

To a r.b. flask (150 cm³), was added Boc-D,L-(5-thiazolyl)glycine ethyl ester (7.00g, 24.70 mmol) to ethanol (c.a. 100cm³) with stirring. 2M Sodium hydroxide solution (25 cm³, 50 mmol) was added and allowed to stir for 1
20 hour. Reaction monitored by TLC (60% hexane/ethyl acetate; s.m. r.f 0.5, prod. r.f. 0.).

Reaction concentrated in vacuo and product taken up in saturated bicarbonate (c.a. 50 cm³) and washed with ethyl acetate (c.a. 30 cm³). Aqueous layer was acidified to pH 2
25 with concentrated hydrochloric acid and product extracted with 3:1 chloroform/isopropanol solution (c.a. 3x60cm³). The organic layer was dried over magnesium sulphate and evaporated to dryness to give an orange solid (4.47g, 17.30 mmol) [74% Yield].

30

¹H NMR (CDCl₃); 1.35 (9H, s), 5.60 (1H, d), 5.83 (1H, d), 7.88 (1H, s), 8.80 (1H, s).

Intermediate PAA-16

N-Boc-D,L-(4-thiazolyl)glycine.**Method PAA-D**

To a solution of N-Boc-D,L-(4-thiazolyl)glycine ethyl ester (0.700g, 2.470 mmol) in methanol (c.a. 15 cm³), was added 2M sodium hydroxide (2.47 cm³, 4.940 mmol) and allowed to stir for 90 minutes. The solution was concentrated in vacuo and taken up in water (c.a. 20 cm³). The aqueous solution was washed with ethyl acetate (c.a. 20 cm³), and then acidified to pH 2 with 5% hydrochloric acid solution (c.a. 50 cm³). The product was extracted with ethyl acetate (c.a. 3x30 cm³), dried over magnesium sulphate, and concentrated in vacuo to yield a pale yellow oil (0.582g, 2.254 mmol) [91% yield].

¹H NMR (CDCl₃) 1.35 (9H, s), 5.5 (1H, d), 5.8 (1H, d), 7.35 (1H, d), 8.75 (1H, d), 9.8-10.2 (1H, br.).

Intermediate PAA-17**N-Boc-D,L-(2-methylthiazol-4-yl)glycine.**

Prepared from N-Boc-D,L-(2-methylthiazol-4-yl)glycine ethyl ester using Method PAA-D.

¹H NMR (CDCl₃) 1.35 (9H, s), 2.6 (3H, s), 5.4 (1H, d), 5.9 (1H, s), 7.1 (1H, s).

25 Intermediate PAA-18**N-Boc-D,L-(2-Benzyloxycarbonylamino-4-thiazolyl)glycine.**

Is prepared from D,L-(2-benzyloxycarbonylamino-4-thiazolyl)glycine. The benzyloxycarbonyl protecting group is removed from the thiazolyl amino group at a convenient point in the preparation of a final compound using a conventional method, such as, for example, heating a solution of an intermediate in HBr/acetic acid at 60 °C, followed by evaporation and a conventional isolation, such as by using SCX ion exchange chromatography.

35

D,L-(2-Benzyloxycarbonylamino-4-thiazolyl)glycine was prepared by the method of Hardy, K.; Harrington, F. and Stachulski, A.

- J. Chem. Soc. Perkin Trans I (1984) 1227-1235.

Intermediate PAA-19

Boc-R-(4-methoxycarbonylphenyl)glycine.

5 To a solution of Boc-R-(4-methoxycarbonylphenyl)glycine methyl ester 692mg in THF 10ml was added a solution of lithium hydroxide hydrate 90mg in water 7ml. The mixture immediately became cloudy and over 15min cleared. After 30min, tlc showed the reaction to be complete. Ethyl acetate 20ml and water
10 20ml were added and the aqueous layer separated. The aqueous solution was acidified with 2M hydrochloric acid and extracted with ethyl acetate (3 x 20ml). The organic solution was then washed with water x 2 and brine x 2, dried with MgSO₄ and evaporated to give the mono-ester (650mg, 98%), pure by tlc.

15

¹H NMR

Intermediate PAA-20

20 Boc-R-(4-Methoxyphenyl)glycine.

Boc-R-(4-hydroxyphenyl)glycine methyl ester was converted to Boc-R-4-methoxyphenylglycine using the alkylation method described by Basak et al. (Tetrahedron Lett. 1998, 39 (27), 4883-4886) followed by hydrolysis of the methyl ester with
25 lithium hydroxide in aqueous THF.

¹H NMR

Intermediate PAA-21

30 N-4-Methoxybenzoyl-N-2,4-dimethoxybenzyl-D,L-(2-trifluoromethylphenyl)glycine.

Prepared from N-4-methoxybenzoyl-N-2,4-dimethoxybenzyl-D,L-(2-trifluoromethylphenyl)glycine methyl ester using Method PAA-B (3 equivalents of LiOH hydrate).

35

¹H NMR

IS-MS, m/e 503.9 (m + 1)

Intermediate PAA-22

N-4-Methoxybenzoyl-N-2,4-dimethoxybenzyl-D,L-(thien-2-yl)-glycine.

5 Method PAA-E

To a solution of 2-thiopheneboronic acid (5.0 g, 39.0 mmol, 1 equiv) in 275 mL of methylene chloride at rt was added 3,4-dimethoxybenzylamine (5.89 mL, 39.0 mmol, 1 equiv) followed by glyoxylic acid monohydrate 3.6 g, 39 mmol, 1 equiv). The
10 reaction was allowed to stir for 56 hours at rt after which time the resultant precipitate was filtered and washed with methylene chloride to afford 9.3 g (78%) of N-2,4-dimethoxybenzyl-D,L-(thien-2-yl)glycine as an off-white solid (IS-MS, m/e 308 (m + 1)).

15 A portion of the solid (5.0 g, 16.3 mmol, 1 equiv.) was dissolved in acetone (20 mL) and 1N sodium hydroxide (20 mL) at rt. To this solution was simultaneously added anisoyl chloride (2.78 g, 16.3 mmol, 1 equiv.) in 20mL of acetone and 2N sodium hydroxide in dropwise fashion. After stirring at rt for 1 hour,
20 the reaction was cooled to 0C and was acidified to pH2-3. Diethyl ether was added and the product was extracted into the organic phase. The combined organic phases were washed with brine, dried over sodium sulfate, filtered, and concentrated to afford 5.1 g (71%) of the titled compound as a white solid.

25 IS-MS, m/e 440 (m + 1).

Intermediate PAA-23

N-Boc-N-2,4-dimethoxybenzyl-D,L-(thien-2-yl)glycine.

30 To a solution of N-2,4-dimethoxybenzyl-D,L-(thien-2-yl)glycine (1.0 g, 3.2 mmol, 1 equiv) in 6 mL of acetone and 6 mL of water at rt was added triethylamine (0.97 mL, 7.0 mmol, 2.1 equiv.) followed by addition of BOC-ON (0.76 g, 3.1 mmol, 0.95 equiv). After stirring at rt overnight, the reaction was
35 diluted with water and washed with ether. The aqueous phase was then acidified with 0.5M citric acid and the product was extracted into diethyl ether. The combined organic phases were

washed with brine, dried over sodium sulfate, filtered, and concentrated to afford 0.38 g (29%) of the titled compound as a crude yellow oil.

5 IS-MS, m/e 408 (m +1).

General Experimental Procedures: Synthesis of Inhibitors

Coupling Method A:

- 10 The coupling of an amine and carboxylic acid to form an amide.
A solution of the amine (1 equiv) and carboxylic acid (1.1 equiv) in a suitable solvent (DMF, and/or methylene chloride) was treated with diethyl cyanophosphonate (1.1 equiv) followed by addition of triethylamine or diisopropylethyl amine (0 to 3
15 equiv) to the mixture. After completion of the reaction by thin-layer chromatography, the mixture was partitioned between a suitable solvent (EtOAc, and/or methylene chloride) and washed with 1N NaOH, water, brine, and concentrated. The crude mixture was then purified, as indicated, or used
20 directly in subsequent transformations.

Coupling Method B:

The coupling of an amine and carboxylic acid to form an amide.

- A solution of the amine (1 equiv) and carboxylic acid (1.1
25 equiv) in a suitable solvent (DMF, and/or methylene chloride) was treated with a carbodiimide-based dehydrating agent (e.g. DCC, or EDCI) (1.0 equiv). In general, addition of a benzotriazole-based reagent (e.g. HOBT, or HOAT) (1 equiv) improved reaction yields. After completion of the reaction by
30 thin-layer chromatography, the mixture was partitioned between a suitable solvent (EtOAc, and/or methylene chloride) and washed with 1N NaOH, water, brine, and concentrated. The crude mixture was then purified, as indicated, or used directly in subsequent transformations.

35

Coupling Method C:

The coupling of an amine and acid chloride to form an amide.

A solution of the amine (1 equiv) in an appropriate solvent

(chloroform, and/or methylene chloride) and pyridine (1-10 equiv) was treated with an acid chloride (1.1 equiv). After completion of the reaction by thin-layer chromatography, the mixture was partitioned between a suitable solvent (EtOAc, 5 methylene chloride, and/or chloroform) and washed with 1N NaOH, water, brine, and concentrated. The crude mixture was then purified, as indicated, or used directly in subsequent transformations.

10 Deprotection Method A:

A mixture of 10% Palladium on carbon and the starting material in an appropriate solvent (EtOAc, EtOH, and/or HOAc) was placed under an atmosphere of hydrogen. Upon completion, the mixture was filtered and the resulting filtrate concentrated. 15 The crude mixture was then purified, as indicated, or used directly in subsequent transformations.

Alkylation Method A:

A solution of the starting material (1 equiv) in 5-10% HOAc in 20 methanol (anhydrous) was treated with the indicated aldehyde or ketone (2-10 equiv) followed by sodium cyanoborohydride (2-10 equiv). After completion, the mixture was concentrated and the residue was either partitioned between a suitable solvent (EtOAc, methylene chloride, and/or chloroform) and washed with 25 1N NaOH, water, brine, and concentrated or directly loaded onto an ion-exchange resin (SCX, Varian) and eluted with methanol followed by 2N ammonia in methanol. Concentration of the later fractions afforded the free base product. The crude mixture was then purified, as indicated, or used directly in 30 subsequent transformations.

Preparation of Starting Materials

1-(Benzyloxycarbonyl-D-phenylglyciny)l)piperidine-4-methanol

35 (Coupling Method A): A solution of benzyloxycarbonyl-D-phenylglycine (5.0 g, 17.5 mmol) and 4-piperidinemethanol (1.83 g, 15.9 mmol) in 90 mL of methylene chloride was cooled

in a methanol/ice bath and then treated with diethyl cyanophosphonate (2.67 mL, 17.5 mmol) followed by ethyl diisopropylamine (3.1 mL). After 5 h, the mixture was concentrated, diluted with EtOAc and saturated aqueous potassium carbonate, and the resulting layers separated. The organic layer was washed (with aqueous potassium carbonate, 1 N HCl, brine), dried over magnesium sulfate, filtered, concentrated, and the residue purified by column chromatography (SiO₂: 70%-80% EtOAc:hexane), affording 1.54 g (25%) of the title compound.

¹NMR

IS-MS, m/e 725 (M + 1).

Analysis for C₂₂H₂₆N₂O₄·0.15 H₂O:

Calcd: C, 68.6; H, 6.9; N, 7.3;

Found: C, 68.5; H, 6.9; N, 7.1.

1-(D-Phenylglycinyl)piperidine-4-methanol

Using Deprotection Method A, 1-(benzyloxycarbonyl-D-phenylglycinyl)piperidine-4-methanol (3.93 g, 29.5 mmol) and 10% palladium on carbon (1.30 g) in 2:1 EtOAc:EtOH (75 mL) afforded 2.31 g (88%) of the title compound.

¹NMR

IS-MS, m/e 249 (M+1).

25 Preparation of Intermediates A-1 - A-3

Intermediate A-1

1-(4-Methoxybenzoyl-D-phenylglycinyl)piperidine-4-methanol.

Using Coupling Method C, 1-(D-phenylglycinyl)piperidine-4-methanol (1.23 g, 4.96 mmol) and p-anisoyl chloride (0.888 g, 5.21 mmol) afforded, after purification by column chromatography (SiO₂: 1:1 to 1:9 hexanes:EtOAc), 1.26 g (66%) of the title compound.

¹NMR

IS-MS, m/e 383 (M+1).

Intermediate A-2

1-(Indole-6-carbonyl-D-phenylglyciny)l)piperidine-4-methanol.

(Coupling Method B): A solution of 1-(D-phenylglyciny)l)piperidine-4-methanol (500 mg, 2.02 mmol), indole-6-carboxylic acid (325 mg, 2.02 mmol), and 1-hydroxy-7-azabenzotriazole (275 mg, 2.02 mmol) in 10 mL of DMF was treated with DCC (415 mg, 2.02 mmol). After 15 h, the mixture was concentrated and the residue dissolved in EtOAc. The organic layer was washed (with 2 N NaOH, water, brine), dried over magnesium sulfate, and concentrated. The residue was purified by column chromatography (SiO₂: EtOAc), affording 780 mg (98%) of the title compound.

¹NMR

IS-MS, m/e 383 (M + 1).

15

Intermediate A-3

1-(3-Chloroindole-6-carbonyl-D-phenylglyciny)l)piperidine-4-methanol.

Using Coupling Method B, 1-(D-phenylglyciny)l)piperidine-4-methanol (9.90 g, 39.9 mmol) and 3-chloroindole-6-carboxylic acid (8.56 g, 43.9 mmol) afforded, after purification by column chromatography (SiO₂: 95% EtOAc in hexane), 8.95 g (53%) of the title compound.

¹NMR

IS-MS, m/e 426 (M + 1).

25

Preparation of Intermediate B-1**Intermediate B-1**

1-(4-Methoxybenzoyl-D-phenylglyciny)l)piperidine-4-carboxaldehyde

A solution of 1-(4-methoxybenzoyl-D-phenylglyciny)l)piperidine-4-methanol (0.800 g, 2.08 mmol) and N-methylmorpholine oxide (0.366 g, 3.13 mmol) in methylene chloride (15 mL) was treated with tetrapropylammonium perruthenate (TPAP, 2 mg). After 14 h, the mixture was treated with additional TPAP (5 mg). After

35

20 h, the mixture was treated with additional TPAP (5 mg). After 32 h, the mixture was loaded directly onto a column and purified by column chromatography (SiO₂: 1:1 to 1:4 hexanes:EtOAc) affording 0.286 g (36%) of the title compound.

5 ¹NMR

IS-MS, m/e 381 (M+1).

Preparation of Intermediates C-2 - C-3

10 Intermediate C-2

1-(Indole-6-carbonyl-D-phenylglyciny1)-4-(methylsulfonyloxymethyl)piperidine.

A solution of 1-(indole-6-carbonyl-D-phenylglyciny1)-piperidine-4-methanol (2.82 g, 7.21 mmol) and triethylamine (2.0 mL) in 40 mL of methylene chloride was treated with methanesulfonyl chloride (1.1 mL, 14.0 mmol). After 2 h, mixture was concentrated and the residue purified by column chromatography (SiO₂: 90% EtOAc in hexane) to afford 2.80 g (83%) of the title compound.

20 ¹NMR

IS-MS, m/e 470 (M + 1).

Intermediate C-3

1-(3-Chloroindole-6-carbonyl-D-phenylglyciny1)-4-(methylsulfonyloxymethyl)piperidine.

Using a procedure similar to that described above for Intermediate C-2, 1-(3-chloroindole-6-carbonyl-D-phenylglyciny1)piperidine-4-methanol (8.95 g, 21.0 mmol) afforded, after purification by column chromatography (SiO₂: 80% to 99% EtOAc in hexane), 2.58 g (24%) of the title compound.

30 ¹NMR

IS-MS, m/e 504 (M + 1).

35 Preparation of Intermediate D-1

4-(Piperidin-1-ylmethyl)piperidine bis-Hydrochloride Salt.

A solution of 4-(piperidin-1-ylmethyl)pyridine (10.0 g, 0.056 mol; prepared using a similar procedure to that described in US430491) and platinum oxide (1.5 g) in 55 mL of ethanol and 18 mL of 12 N HCl was placed under an atmosphere of hydrogen 5 (4.1 bar, 60 psig). After 15 h, the mixture was filtered, concentrated, and residue triturated with methanol affording 9.0 g of the title compound as a bis hydrochloride salt.

¹NMR

IS-MS, m/e 183 (M + 1).

10

1-(Benzyloxycarbonyl-D-phenylglyciny)-4-[(piperidin-1-yl)-methyl]piperidine.

Using Coupling Method A, benzyloxycarbonyl-D-phenylglycine 15 (17.1 g, 60.1 mmol) and 4-(piperidin-1-ylmethyl)piperidine (10.0 g, 54.6 mmol) afforded, after purification by column chromatography (SiO₂: 2% to 3% [2 N ammonia in methanol]:methylene chloride) 10.7 g (43%) of the title compound.

20 ¹NMR

IS-MS, m/e 451 (M + 1).

Analysis for C₂₇H₃₅N₃O₃:

Calcd: C, 72.1; H, 7.8; N, 9.3;

Found: C, 72.0; H, 7.7; N, 9.4.

25

Intermediate D-1.

1-(D-Phenylglyciny)-4-[(piperidin-1-yl)methyl]piperidine.

Using Deprotection Method A, 1-(benzyloxycarbonyl-D-phenylglyciny)-4-[(piperidin-1-yl)methyl]piperidine (10.7 g, 30 23.8 mmol) and 10% palladium on carbon (1.35 g) in 200 mL of 1:1 EtOH:EtOAc afforded the title compound.

¹NMR

IS-MS, m/e 315 (M + 1).

35 Preparation of Examples 1-5

General Procedure: Unless otherwise indicated, the product of

Examples 1-5 was obtained from the indicated amine and 1-(4-methoxybenzoyl-D-phenylglyciny)l)piperidine-4-carboxaldehyde (Intermediate B-1) using Alkylation Method A.

5 **Example 1.**

1-[(4-Methoxybenzoyl-D-phenylglyciny)l]-4-[(isopropylamino)-methyl]piperidine hydrochloride

1-(4-Methoxybenzoyl-D-phenylglyciny)l)piperidine-4-carboxaldehyde (0.050 g, 0.131 mmol) and isopropylamine
10 afforded, after treatment of the isolated product with excess hydrochloric acid in methanol and concentration, 37 mg of the title compound as a hydrochloride salt.

¹NMR

IS-MS, m/e 424 (M+1)

15

Example 2.

1-(4-Methoxybenzoyl-D-phenylglyciny)l)-4-[(dimethylamino)-methyl]piperidine

1-(4-Methoxybenzoyl-D-phenylglyciny)l)piperidine-4-
20 carboxaldehyde (0.050 g, 0.131 mmol) and dimethylamine afforded 25 mg (47%) of the title compound.

¹NMR

IS-MS, m/e 410 (M+1)

25 **Example 3.**

1-[(4-Methoxybenzoyl-D-phenylglyciny)l]-4-[(N,N-diethyl-amino)methyl]piperidine hydrochloride

1-(4-Methoxybenzoyl-D-phenylglyciny)l)piperidine-4-carboxaldehyde (0.050 g, 0.131 mmol) and diethylamine
30 afforded, after treatment of isolated product with excess hydrochloric acid in methanol and concentration, 42 mg of the title compound as a hydrochloride salt.

¹NMR

IS-MS, m/e 438 (M+1)

35

Example 4.

1-[(4-Methoxybenzoyl-D-phenylglyciny)]-4-[(1-pyrrolidinyl)-methyl]piperidine

1-(4-Methoxybenzoyl-D-phenylglyciny)piperidine-4-carboxaldehyde (0.050 g, 0.131 mmol) and pyrrolidine afforded 27 mg (47%) of the title compound.

¹NMR

IS-MS, m/e 436 (M+1)

10 **Example 5.**

1-[(4-Methoxybenzoyl-D-phenylglyciny)]-4-[(3-pyrrolin-1-yl)-methyl]piperidine hydrochloride

1-(4-Methoxybenzoyl-D-phenylglyciny)piperidine-4-carboxaldehyde (0.050 g, 0.131 mmol) and 3-pyrroline afforded, after treatment of isolated product with excess hydrochloric acid in methanol and concentration, 43 mg of the title compound as a hydrochloride salt.

¹NMR

IS-MS, m/e 434 (M+1)

20

Preparation of Examples 6-18

General Procedure: Unless otherwise indicated, the product of Examples 6-18 was obtained from the indicated amine and 1-(indole-6-carbonyl-D-phenylglyciny)-4-(methylsulfonyloxymethyl)piperidine (Intermediate C-2) or 1-(3-chloroindole-6-carbonyl-D-phenylglyciny)-4-(methylsulfonyloxymethyl)piperidine (Intermediate C-3) using a procedure similar to that described in Example 6.

30

Example 6.

1-(Indole-6-carbonyl-D-phenylglyciny)-4-[(isopropylamino)-methyl]piperidine Trifluoroacetate Salt.

A solution of 1-(indole-6-carbonyl-D-phenylglyciny)-4-(methylsulfonyloxymethyl)piperidine (100 mg, 0.213 mmol) and isopropylamine (0.18 mL, 2.1 mmol) in 1 mL of THF was treated

with potassium carbonate (60 mg) and sodium iodide (32 mg, 0.21 mmol), and the mixture was heated at reflux. After 16 h, the mixture was concentrated and the residue purified by rpHPLC chromatography affording 24 mg (21%) of the title compound as a trifluoroacetate salt.

¹NMR

IS-MS, m/e 433 (M + 1).

Example 7.

10 1-(Indole-6-carbonyl-D-phenylglyciny1)-4-[4-(pyrrolidin-1-yl)methyl]piperidine Trifluoroacetate Salt.

Intermediate C-2 (200 mg, 0.426 mmol) and pyrrolidine (0.85 mmol) afforded, after purification by rpHPLC chromatography, 38 mg (16%) of the title compound as a trifluoroacetate salt.

15 ¹NMR

Example 8.

1-(Indole-6-carbonyl-D-phenylglyciny1)-4-[(diethylamino)-methyl]piperidine Trifluoroacetate Salt.

20 Intermediate C-2 (100 mg, 0.213 mmol) and diethylamine (2.1 mmol) afforded, after purification by rpHPLC chromatography, 59 mg (49%) of the title compound as a trifluoroacetate salt.

¹NMR

IS-MS, m/e 447 (M + 1).

25

Example 9.

1-(Indole-6-carbonyl-D-phenylglyciny1)-4-[(piperidin-1-yl)-methyl]piperidine Trifluoroacetate Salt.

Intermediate C-2 (100 mg, 0.213 mmol) and piperidine (2.3 mmol) afforded, after purification by rpHPLC chromatography, 16 mg (13%) of the title compound as a trifluoroacetate salt.

¹NMR

IS-MS, m/e 459 (M + 1).

35 **Example 10.**

1-(Indole-6-carbonyl-D-phenylglyciny1)-4-[(4-hydroxypiperidin-

1-yl)methyl]piperidine Trifluoroacetate Salt.

Intermediate C-2 (100 mg, 0.213 mmol) and 4-hydroxypiperidine (2.3 mmol) afforded, after purification by rpHPLC chromatography, 32 mg (25%) of the title compound as a trifluoroacetate salt.

¹NMR

IS-MS, m/e 475 (M + 1).

Example 11.

10 **1-(Indole-6-carbonyl-D-phenylglyciny)-4-[(piperazin-1-yl)-methyl]piperidine Trifluoroacetate Salt.**

Intermediate C-2 (100 mg, 0.213 mmol) and piperazine (2.3 mmol) afforded, after purification by rpHPLC chromatography, 85 mg (70%) of the title compound as a trifluoroacetate salt.

15 ¹NMR

IS-MS, m/e 460 (M + 1).

Example 12.

1-(Indole-6-carbonyl-D-phenylglyciny)-4-[(4-methylpiperazin-1-yl)methyl]piperidine Trifluoroacetate Salt.

Intermediate C-2 (100 mg, 0.213 mmol) and 1-methylpiperazine (2.3 mmol) afforded, after purification by rpHPLC chromatography, 66 mg (53%) of the title compound as a trifluoroacetate salt.

25 ¹NMR

IS-MS, m/e 474 (M + 1).

Example 13.

1-(Indole-6-carbonyl-D-phenylglyciny)-4-[(3-hydroxypyrrolidin-1-yl)methyl]piperidine Trifluoroacetate Salt.

Intermediate C-2 (100 mg, 0.213 mmol) and 3-hydroxypyrrolidine (2.3 mmol) afforded, after purification by rpHPLC chromatography, 36 mg (30%) of the title compound as a trifluoroacetate salt.

35 ¹NMR

IS-MS, m/e 461 (M + 1).

Example 14.

1-(Indole-6-carbonyl-D-phenylglyciny1)-4-[(R)-(3-hydroxy-methylpyrrolidin-1-yl)methyl]piperidine Trifluoroacetate Salt.

- 5 Intermediate C-2 (100 mg, 0.213 mmol) and (R)-3-hydroxymethylpyrrolidine (2.3 mmol) afforded, after purification by rpHPLC chromatography, 32 mg (26%) of the title compound as a trifluoroacetate salt.

¹NMR

- 10 IS-MS, m/e 475 (M + 1).

Example 15.

1-(Indole-6-carbonyl-D-phenylglyciny1)-4-[(S)-(3-hydroxy-methylpyrrolidin-1-yl)methyl]piperidine Trifluoroacetate Salt.

- 15 Intermediate C-2 (100 mg, 0.213 mmol) and (S)-3-hydroxymethylpyrrolidine (2.3 mmol) afforded, after purification by rpHPLC chromatography, 36 mg (29%) of the title compound as a trifluoroacetate salt.

¹NMR

- 20 IS-MS, m/e 475 (M + 1).

Example 16.

1-(Indole-6-carbonyl-D-phenylglyciny1)-4-[(4-hydroxymethyl-piperidin-1-yl)methyl]piperidine Trifluoroacetate Salt.

- 25 Intermediate C-2 (100 mg, 0.213 mmol) and 4-hydroxymethylpiperidine (2.3 mmol) afforded, after purification by rpHPLC chromatography, 28 mg (22%) of the title compound as a trifluoroacetate salt.

¹NMR

- 30 IS-MS, m/e 489 (M + 1).

Example 17.

1-(3-Chloroindole-6-carbonyl-D-phenylglyciny1)-4-[(piperidin-1-yl)methyl]piperidine Hydrochloride Salt.

- 35 Intermediate C-3 (1.0 g, 2.0 mmol) and piperidine (6.0 mmol) afforded, after purification by column chromatography (SiO₂:

2% to 4% [2 N ammonia in methanol]:methylene chloride) and salt formation with hydrochloric acid, 443 mg (41%) of the title compound as a hydrochloride salt.

¹NMR

5 IS-MS, m/e 493 (M + 1).

Example 18.

1-(3-Chloroindole-6-carbonyl-D-phenylglyciny)-4-
[(3-hydroxypiperidin-1-yl)methyl]piperidine.

10 Intermediate C-3 (1.50 g, 3.0 mmol) and 3-hydroxypiperidine (9.0 mmol) afforded, after purification by column chromatography (SiO₂: 2% to 3% [2 N ammonia in methanol]:methylene chloride), 1.10 g of the title compound.

¹NMR

15 IS-MS, m/e 507 (M + 1).

Preparation of Examples 19-21

General Procedure: Unless otherwise indicated, the product of
20 Examples 19-21 was obtained from the indicated carboxylic acid and 1-(D-phenylglyciny)-4-[(piperidin-1-yl)methyl]piperidine (Intermediate D-1) using a procedure similar to that described in Example 19.

25 Example 19.

1-(Indole-6-carbonyl-D-phenylglyciny)-4-[(piperidin-1-yl)-
methyl]piperidine.

(Coupling Method B): A solution of 1-(D-phenylglyciny)-4-
[(piperidin-1-yl)methyl]piperidine (4.00 g, 12.7 mmol) and
30 indole-6-carboxylic acid (2.25 g, 13.9 mmol) in 60 mL of DMF was treated with HOBT (1.88 g, 13.9 mmol), the mixture cooled to 0 °C, and then treated with DCC (2.87 g, 13.9 mmol). After 15 h, the mixture was diluted with EtOAc, filtered, and the filtrate concentrated. The residue was purified by column
35 chromatography (SiO₂; 2% to 3.5% [2 N ammonia in methanol]:methylene chloride) to afford 3.1 g (53%) of the title compound.

¹NMR

IS-MS, m/e 459 (M + 1).

Example 20.

- 5 1-(3-Methylindole-6-carbonyl-D-phenylglyciny1)-4-[(piperidin-1-yl)methyl]piperidine Hydrochloride Salt.

Intermediate D-1 (2.00 g, 6.35 mmol) and 3-methylindole-6-carboxylic acid (1.22 g, 6.98 mmol) afforded, after formation of the hydrochloride salt, 1.29 g (41%) of the title
10 compound.

¹NMR

IS-MS, m/e 473 (M + 1).

Analysis for C₂₉H₃₆N₄O₂·HCl·0.75 H₂O:

Calcd: C, 66.7; H, 7.4; N, 10.7;
15 Found: C, 66.7; H, 7.2; N, 10.8.

Example 21.

- 1-(5-Chloroindole-2-carbonyl-D-phenylglyciny1)-4-[(piperidin-1-yl)methyl]piperidine Hydrochloride Salt.

20 Intermediate D-1 and 5-chloro-1H-indole-2-carboxylic acid (1.36 g, 6.98 mmol) afforded, after formation of the hydrochloride salt, 1.52 g (45%) of the title compound.

¹NMR

IS-MS, m/e 493 (M + 1).

- 25 Analysis for C₂₈H₃₃ClN₄O₂·HCl·0.75 H₂O:

Calcd: C, 61.9; H, 6.6; N, 10.3;
Found: C, 61.8; H, 6.4; N, 10.4.

The following compounds are prepared using similar
30 procedures to those described above and the requisite starting materials:

- 1-[Indole-6-carbonyl-D,L-(2-methoxyphenyl)glyciny1]-4-
[(piperidin-1-yl)methyl]piperidine

35

- 1-[Indole-6-carbonyl-D,L-(5-thiazoyl)glyciny1]-4-[(piperidin-1-yl)methyl]piperidine

1- [Indole-6-carbonyl-D,L- (2-aminothiazol-4-yl)glycinyll] -4-
[(piperidin-1-yl)methyl]piperidine

5 1- [Indole-6-carbonyl-D,L- (2-methylthiazol-4-yl)glycinyll] -4-
[(piperidin-1-yl)methyl]piperidine

1- [3-Methylindole-6-carbonyl-D,L- (4-pyridyl)glycinyll] -4-
[(piperidin-1-yl)methyl]piperidine

10

1- [3-Chloroindole-6-carbonyl-D,L- (4-pyridyl)glycinyll] -4-
[(piperidin-1-yl)methyl]piperidine

1- [Indole-6-carbonyl-D,L- (2-methoxyphenyl)glycinyll] -4-
15 [(piperidin-1-yl)methyl]piperidine

1- [3-Methylindole-6-carbonyl-D,L- (2-methoxyphenyl)glycinyll] -4-
[(piperidin-1-yl)methyl]piperidine

20 1- [3-Chloroindole-6-carbonyl-D,L- (2-methoxyphenyl)glycinyll] -4-
[(piperidin-1-yl)methyl]piperidine

1- [Indole-6-carbonyl-D,L- (1-naphthyl)glycinyll] -4- [(piperidin-
1-yl)methyl]piperidine

25

1- [3-Methylindole-6-carbonyl-D,L- (1-naphthyl)glycinyll] -4-
[(piperidin-1-yl)methyl]piperidine

1- [3-Chloroindole-6-carbonyl-D,L- (1-naphthyl)glycinyll] -4-
30 [(piperidin-1-yl)methyl]piperidine

1- [Indole-6-carbonyl-D,L- (2-chlorophenyl)glycinyll] -4-

[(piperidin-1-yl)methyl]piperidine

1- [3-Methylindole-6-carbonyl-D,L- (2-chlorophenyl)glyciny] -4-
[(piperidin-1-yl)methyl]piperidine

5

1- [3-Chloroindole-6-carbonyl-D,L- (2-chlorophenyl)glyciny] -4-
[(piperidin-1-yl)methyl]piperidine

1- [Indole-6-carbonyl-D,L- (8-quinolinyl)glyciny] -4-
10 [(piperidin-1-yl)methyl]piperidine

1- [3-Methylindole-6-carbonyl-D,L- (8-quinolinyl)glyciny] -4-
[(piperidin-1-yl)methyl]piperidine

15 1- [3-Chloroindole-6-carbonyl-D,L- (8-quinolinyl)glyciny] -4-
[(piperidin-1-yl)methyl]piperidine

1- [Indole-6-carbonyl-D,L- (4-quinolinyl)glyciny] -4-
[(piperidin-1-yl)methyl]piperidine

20

1- [3-Methylindole-6-carbonyl-D,L- (4-quinolinyl)glyciny] -4-
[(piperidin-1-yl)methyl]piperidine

1- [3-Chloroindole-6-carbonyl-D,L- (4-quinolinyl)glyciny] -4-
25 [(piperidin-1-yl)methyl]piperidine

Assay protocols

30 Enzyme Inhibition assays:

The ability of a test compound to inhibit factor Xa may be evaluated in one or more of the following Enzyme Inhibition

assays, or in other standard assays known to those skilled in the art.

Enzyme Inhibition Assay 1

5

Enzyme assays were carried out at room temperature in 0.1M phosphate buffer, pH7.4 according to the method of Tapparelli et al (J. Biol. Chem. 1993,268,4734-4741). Purified human factor Xa, trypsin, thrombin and plasmin were purchased from

10 Alexis Corporation, Nottingham, UK. Urokinase was purchased from Calbiochem, Nottingham, UK. Chromogenic substrates for these enzymes; pefachrome-FXA, pefachrome-TRY, pefachrome-TH, pefachrome-PL and pefachrome-UK were purchased from Pentapharm AG, Basel, Switzerland. Product (p-nitroaniline) was

15 quantified by adsorption at 405nm in 96 well microplates using a Dynatech MR5000 reader (Dynex Ltd, Billingshurst, UK). K_m and K_i were calculated using SAS PROC NLIN (SAS Institute, Cary, NC, USA, Release 6.11) K_m values were determined as 100.9 μ M for factor Xa/pefachrome-FXA and 81.6 μ M for

20 trypsin/pefachrome-TRY. Inhibitor stock solutions were prepared at 40mM in Me2SO and tested at 500 μ M, 50 μ M and 5 μ M. Accuracy of K_i measurements was confirmed by comparison with K_i values of known inhibitors of factor Xa and trypsin.

25 In agreement with published data, benzamidine inhibited factor Xa, trypsin, thrombin, plasmin and urokinase with K_i values of 155 μ M, 21 μ M, 330nM, 200nM and 100nM respectively. NAPAP inhibited thrombin with a K_i value of 3nM. Compounds of the invention were found to have activity in these assays.

30

Enzyme Inhibition Assay 2

Human factor Xa and human thrombin were purchased from Enzyme Research Laboratories (South Bend, Indiana, USA). Other

35 proteases were from other commercial sources. Chromogenic para-nitroanilide peptide protease substrates were purchased from Midwest Biotech (Fishers, Indiana, USA).

The binding affinities for human factor Xa were measured as apparent association constants (Kass) derived from protease inhibition kinetics as described previously.^{a,b,c,d} The apparent Kass values were obtained using automated (BioMek-1000) dilutions of inhibitors (Kass determinations are performed in triplicate at each of four-eight inhibitor concentrations) into 96-well plates and chromogenic substrate hydrolysis rates determined at 405 nm using a Thermomax plate reader from Molecular Devices (San Francisco). For factor Xa inhibition, the assay protocol was: 50 µl buffer (0.06 M tris, 0.3 M NaCl, pH 7.4); 25 µl inhibitor test solution (in MeOH); 25 µl human factor Xa (32 nM in 0.03 M tris, 0.15 M NaCl, 1 mg/ml HSA); finally, 150 µl BzIleGluGlyArgpNA (0.3 mM in water) added within 2 min to start hydrolysis. Final factor Xa was 3.2 nM. Free [Xa] and bound [Xa] were determined from linear standard curves on the same plate by use of SoftmaxPro software for each inhibitor concentration and apparent Kass calculated for each inhibitor concentration which produced hydrolysis inhibition between 20% and 80% of the control (3.2 nM factor Xa):

$$\text{apparent Kass} = \frac{[E:I]}{[E_f][I_f]} = \frac{[E_b]}{[E_f][I^0 - I_b]}$$

The apparent Kass values so obtained are approximately the inverse of the K_i for the respective inhibitors [$1/\text{appKass} = \text{app } K_i$]. The variability of mean apparent Kass values determined at the single substrate concentration was $\pm 15\%$. The assay system K_m was measured as 0.347 ± 0.031 mM [$n=4$]; and V_{\max} was 13.11 ± 0.76 µM/min.

Kass values were determined with thrombin and other proteases using the same protocol with the following enzyme and substrate concentrations: thrombin 5.9 nM with 0.2 mM BzPheValArgpNA; XIa 1.2 nM with 0.4 mM pyroGluProArgpNA; XIIa 10 nM with 0.2 mM HDProPheArgpNA; plasmin 3.4 nM with 0.5 mM HDValLeuLyspNA; nt-PA 1.2 nM with 0.8 mM HDIleProArgpNA; and

urokinase 0.4 nM with 0.4 mM pyroGluGlyArgpNA; aPC 3 nM with 0.174 mM pyroGluProArgpNA; plasma kallikrein 1.9 nM with D-ProPheArgpNA; bovine trypsin 1.4 nM with 0.18 mM BzPheValArgpNA.

5

Citations

- (a) Sall DJ, JA Bastian, SL Briggs, JA Buben, NY Chirgadze, DK Clawson, ML Denny, DD Giera, DS Gifford-
10 Moore, RW Harper, KL Hauser, VJ Klimkowski, TJ Kohn, H-S Lin, JR McCowan, AD Palkowitz, GF Smith, ME Richett, K Takeuchi, KJ Thrasher, JM Tinsley, BG Utterback, S-CB Yan, M Zhang. Dibasic Benzo[b]thiophenes Derivatives as a Novel Class of Active Site Directed Thrombin
15 Inhibitors. 1. Determination of the Serine Protease Selectivity, Structure-Activity Relationships and Binding Orientation. J Med Chem 40 3489-3493 (1997).
- (b) Smith GF, TJ Craft, DS Gifford-Moore, WJ Coffman, KD Kurz,
20 E Roberts, RT Shuman, GE Sandusky, ND Jones, N Chirgadze, and CV Jackson. A Family of Arginal Thrombin Inhibitors Related to Efegatran. Sem. Thrombos. Hemost. 22, 173-183 (1996).
- (c) Smith GF, DS Gifford-Moore, TJ Craft, N Chirgadze, KJ
25 Ruterbories, TD Lindstrom, JH Satterwhite. Efegatran: A New Cardiovascular Anticoagulant. In New Anticoagulants for the Cardiovascular Patient. Ed. R Pifarre. Hanley & Belfus, Inc., Philadelphia (1997) pp 265-300.
- (d) Sall DJ, JA Bastian, NY Chirgadze, ML Denny, MJ
30 Fisher, DS Gifford-Moore, RW Harper, VJ Klimkowski, TJ Kohn, HS Lin, JR McCowan, ME Richett, GF Smith, K Takeuchi, JE Toth, M Zhang. Diamino Benzo[b]thiophene Derivatives as a Novel Class of Active Site Directed
35 Thrombin Inhibitors: 5. Potency, Efficacy and

Pharmacokinetic Properties of Modified C-3 Side Chain
Derivatives. In press, J Med Chem (1999).

In general, the compounds of formula (I) exemplified herein
5 have been found to exhibit a K_i of 10 μM or less in Assay 1
and/or a K_{ass} of at least 0.1×10^6 L/mole in Assay 2.

The ability of a test compound to elongate Partial
Thromboplastin Time (Prothrombin Time) may be evaluated in the
10 following test protocols.

Partial Thromboplastin Time (Prothrombin) Test Protocol

Venous blood was collected into 3.2% (0.109m) trisodium
15 citrate vacutainer tubes at 1 volume of anticoagulant to nine
volumes of blood. The blood cells were separated by
centrifugation at 700g for ten minutes to yield plasma, which
was frozen at 70°C until required.

To perform the test, 100 μl of plasma was pipetted into in a
20 glass test tube, 1 μl of test compound in DMSO was added, and
allowed to warm to 37° over two minutes. 100 μl of warm (37°)
Manchester (tissue thromboplasin) reagent (Helena Biosciences,
UK) was added, allowed to equilibrate for two minutes. 100 μl
of warm (37°) 25mM calcium chloride solution was added to
25 initiate clotting. The test tube was tilted three times
through a 90° angle every five seconds to mix the reagents and
the time to clot formation recorded. Data from a series of
observations and test compound concentrations are analysed by
a SAS statistical analysis program and a CT2 (Concentration
30 required to double clotting time) for each compound is
generated.

Compounds of the invention were found to significantly
elongate the partial thromboplastin time (Prothrombin time).
35

Alternative Prothrombin Time and APTT Protocols

Coagulation Determinations. Prothrombin Times and APTT values were determined in HUMAN PLASMA with a STA instrument (Stago).

BioPT is a special non-plasma clotting assay triggered with human tissue factor (Innovin). Possible binding to albumen or to lipid was assessed by comparing the BioPT effects in the presence/absence of 30 mg/ml human albumen (HSA) and 1 mg/ml phosphatidyl choline (PC). Inhibitors were delivered in 50% MeOH vehicle.

10 APTT ASSAY

75 µl plasma Citrol *Baxter-Dade* Citrated Normal

Human Plasma

25 µl test sol'n

75 µl Actin *Baxter-Dade* Activated Cephaloplastin incubate 2 min

15 min. @ 37°

75 µl CaCl₂ (0.02 M)

PT ASSAY

75 µl plasma

20 25 µl test sol'n


75 µl saline _____ incubate 1 min. @ 37° C

75 µl Innovin *Baxter-Dade* Recombinant Human Tissue Factor

Compounds of the invention were found to be potent inhibitors of factor Xa.

Claims

1. A serine protease inhibitor compound of formula (I)



5

wherein:

R_2 is a 5 or 6 membered aromatic carbon ring optionally interrupted by a nitrogen, oxygen or sulphur ring atom, optionally being substituted in the 3 and/or 4 position (in relation to the point of attachment of X-X) by halo, nitro, thiol, haloalkoxy, hydrazido, alkylhydrazido, amino, cyano, haloalkyl, alkylthio, alkenyl, alkynyl, acylamino, tri or difluoromethoxy, carboxy, acyloxy, MeSO_2 - or R_1 , or the substituents at the 3 and 4 positions taken together form a fused ring which is a 5 or 6 membered carbocyclic or heterocyclic ring optionally substituted by halo, haloalkoxy, haloalkyl, cyano, nitro, amino, hydrazido, alkylthio, alkenyl, alkynyl or R_{1j} , and optionally substituted in the position alpha to the X-X group (i.e. 6 position for a six membered aromatic ring etc) by amino, hydroxy, halo, alkyl, carboxy, alkoxy, carbonyl, cyano, amido, aminoalkyl, alkoxy or alkylthio with the proviso that R_2 cannot be aminoisoquinolyl;

each X independently is a C, N, O or S atom or a CO, CR_{1a} , $\text{C(R}_{1a})_2$ or NR_{1a} group, at least one X being C, CO, CR_{1a} or $\text{C(R}_{1a})_2$;

each R_{1a} independently represents hydrogen or hydroxyl, alkoxy, alkyl, aminoalkyl, hydroxyalkyl alkoxyalkyl, alkoxy, carbonyl, alkylaminocarbonyl, alkoxy, carbonyl, amino, acyloxymethoxycarbonyl or alkylamino optionally substituted by hydroxy, alkylamino, alkoxy, oxo, aryl or cycloalkyl;

R_1 is as defined for R_{1a} , provided that R_1 is not unsubstituted aminoalkyl;

Y (the α -atom) is a nitrogen atom or a CR_{1b} group;

Cy is a saturated or unsaturated, mono or poly cyclic, homo or heterocyclic group, preferably containing 5 to 10 ring atoms and optionally substituted by groups R_{3a} or phenyl


optionally substituted by R_{3a} or $R_{3i}X_i$;

each R_{3a} independently is R_{1c} , amino, halo, cyano, nitro, thiol, alkylthio, alkylsulphonyl, alkylsulphenyl, triazolyl, imidazolyl, tetrazolyl, hydrazido, alkylimidazolyl, thiazolyl, alkylthiazolyl, alkylloxazolyl, oxazolyl, alkylsulphonamido, alkylaminosulphonyl, aminosulphonyl, haloalkoxy, haloalkyl, a group of the formula $-C(X^3)N(R^{11})R^{12}$ (wherein X^3 is O or S; and R^{11} and R^{12} are independently selected from hydrogen, methyl or ethyl or together with the nitrogen atom to which they are attached form a pyrrolidin-1-yl, piperidin-1-yl or morpholino group), or $-OCH_2O-$ which is bonded to two adjacent ring atoms in Cy;

X_i is a bond, O, NH or CH_2 ;

R_{3i} is phenyl, pyridyl or pyrimidinyl optionally substituted by R_{3a} ;

R_{1b} , R_{1c} and R_{1j} are as defined for R_{1a} ; and $-L-Lp(D)_n$ is




q is 1 or 2;

Q is methylene; and R_q is NR_aR_b in which each of R_a and R_b independently is hydrogen or C_{1-3} alkyl; or one of R_a and R_b is hydrogen or methyl and the other of R_a and R_b is (3-6C)cycloalkyl, pyrid-4-yl, $-CH_2-R_c$ or $-CH_2-R_d$ in which R_c is pyridyl or phenyl (which phenyl may bear a fluoro, chloro, methyl, $CONH_2$, SO_2NH_2 , methylaminosulphonyl, dimethylaminosulphonyl, methylsulphonylamino, methoxy or methylsulphonyl substituent) and in which R_d is isopropyl or cyclopentyl, or NR_aR_b is azetidino, pyrrolidino, piperidino, morpholino, thiomorpholino, piperazino, or tetrahydro-1,4-diazepino [in which a pyrrolidino or piperidino may be a 3,4-didehydro derivative and in which a azetidino, pyrrolidino, piperidino, morpholino, thiomorpholino, piperazino, or tetrahydro-1,4-diazepino may be optionally substituted on a ring carbon atom by hydroxy, amino, (1-3C)alkoxy, (1-3C)hydroxyalkyl, (1-3C)alkyl, carboxy,

methoxycarbonyl or ethoxycarbonyl (provided that the amino, hydroxy or alkoxy substituent is not on a ring carbon atom which is included in a double bond, or adjacent to a ring oxygen, sulfur or nitrogen atom) and in which the piperazino or tetrahydro-1,4-diazepino may bear a methyl group at the 4-position];
or a physiologically-tolerable salt thereof.

2. A compound according to claim 1 wherein the azetidino, pyrrolidino, piperidino, morpholino, thiomorpholino, piperazino or tetrahydro-1,4-diazepino in NR_aR_b is optionally substituted on a ring carbon atom by methyl, hydroxy or hydroxymethyl.

3. A compound according to claim 1 wherein $-L-Lp(D)_n$ is of the formula:



wherein:


q is 1 or 2;

Q is methylene; and R_q is NR_aR_b in which each of R_a and R_b independently is hydrogen or C_{1-3} alkyl; or one of R_a and R_b is hydrogen or methyl and the other of R_a and R_b is $-CH_2-R_c$ or $-CH_2-R_d$ in which R_c is pyridyl or phenyl (which phenyl may bear a fluoro, chloro, methyl, $CONH_2$, SO_2NH_2 , methylaminosulphonyl, dimethylaminosulphonyl, methylsulphonylamino, methoxy or methylsulphonyl substituent) and in which R_d is isopropyl or cyclopentyl, or NR_aR_b is pyrrolidino, piperidino, morpholino, piperazino, or tetrahydro-1,4-diazepino in which a pyrrolidino or piperidino may be a 3,4-didehydro derivative and in which a pyrrolidino, piperidino, piperazino, or tetrahydro-1,4-diazepino may bear a methyl group at the 4-position;
or a physiologically-tolerable salt thereof.

4. A compound according to any of claims 1 to 3 wherein q is

2.

5. A compound according to any of claims 1 to 4 wherein -L-Lp(D)_n is of the formula:



5

wherein:

q is 1 or 2;


Q is methylene; and R_q is NR_aR_b in which each of R_a and R_b independently is hydrogen or C₁₋₃alkyl; or one of R_a and R_b is hydrogen and the other is (3-6C)cycloalkyl or pyrid-4-yl; or NR_aR_b is azetidino, pyrrolidino, piperidino or piperazino [in which a pyrrolidino or piperidino may be a 3,4-didehydro derivative and in which a azetidino, pyrrolidino, piperidino or piperazino may be optionally substituted on a ring carbon atom by methyl, hydroxy or hydroxymethyl (provided that the hydroxy substituent is not on a ring carbon atom which is included in a double bond, or adjacent to a ring nitrogen atom) and in which the piperazino may bear a methyl group at the 4-position].

20

6. A compound according to claim 5 wherein:

R_q is NR_aR_b in which R_a is hydrogen or C₁₋₃alkyl and R_b is C₁₋₃alkyl; or R_a is hydrogen and R_b is (3-6C)cycloalkyl or pyrid-4-yl; or NR_aR_b is azetidino, pyrrolidino, piperidino, morpholino, thiomorpholino or piperazino [in which a pyrrolidino, piperidino or piperazino may be optionally substituted on a ring carbon atom by hydroxy or hydroxymethyl (provided that the hydroxy substituent is not on a ring carbon atom which is adjacent to a ring nitrogen atom) and in which the piperazino may bear a methyl group at the 4-position].

7. A compound according to any one of claims 1 to 4 wherein -Lp(D)_n is selected from the following formulae:




wherein:

5 m represents 0 or 1;

and when R_3 is present as a substituent on a saturated ring, it is selected from hydrogen, hydroxy, amino, (1-3C)alkoxy, (1-3C)hydroxyalkyl, (1-3C)alkyl, carboxy, methoxycarbonyl and ethoxycarbonyl.

10

8. A compound according to any of claims 1 to 4 wherein -Lp(D)n is selected from the following formulae:



15

9. A compound according to any of claims 1 to 5 wherein R_q is selected from dimethylamino, diethylamino, prop-2-ylamino, pyrrolidino, 3-pyrrolino, 3-hydroxypyrrolidino, 3-hydroxymethylpyrrolidino, piperidino, 3-hydroxypiperidino, 4-

hydroxypiperidino, 4-hydroxymethylpiperidino, piperazino and 4-methylpiperazino.

10. A compound according to any of claims 1 to 5 wherein R_q is selected from dimethylamino, diethylamino, prop-2-ylamino, pyrrolidino, 3-pyrrolino, 3-hydroxypyrrolidino, 3-hydroxymethylpyrrolidino, 3(S)-hydroxypyrrolidino, 3(S)-hydroxymethylpyrrolidino, 3(R)-hydroxymethylpyrrolidino, piperidino, 4-hydroxypiperidino, 4-hydroxymethylpiperidino, 3-hydroxypiperidino, piperazino and 4-methylpiperazino.

11. A compound according to any one of claims 1 to 10 wherein the 5 or 6 membered aromatic carbon ring optionally interrupted by a nitrogen, oxygen or sulphur ring atom, in R₂, is selected from phenyl, pyrrolyl, pyridyl, pyrazinyl, furyl and thienyl (optionally substituted as defined in claim 1).

12. A compound according to any one of claims 1 to 11 wherein R₂ is phenyl (optionally substituted as defined in claim 1).

20

13. A compound according to any one of claims 1 to 12 wherein R₂ is naphthyl, benzimidazolyl, isoquinolinyl, indolyl, indazolyl, 3,4-methylenedioxyphenyl, dihydroindolyl, benzothiazolyl, benzo[b]thiophenyl, benzofuryl, imidazo[1,2-a]pyrimidinyl, tetrahydroimidazo[1,2-a]pyrimidinyl or benzisoxazolyl (each of which is optionally substituted as defined in claim 1).


14. A compound according to any one of claims 1 to 13 wherein R₂ is phenyl, thien-2-yl, naphthyl, indol-2-yl, indol-6-yl, benzo[b]furan-5-yl, benzo[b]thiophen-2-yl or benzimidazol-2-yl (each of which is optionally substituted as defined in claim 1).

15. A compound according to any one of claims 1 to 14 wherein optional substituents for R₂ are selected from: fluoro, chloro, bromo, iodo, nitro, thiol, difluoromethoxy, trifluoromethoxy, hydrazido, methylhydrazido, amino, cyano,

trifluoromethyl, methylthio, vinyl, ethynyl, acetylamino, carboxy, acetoxy, hydroxy, methyl, ethyl, amido (CONH_2), aminomethyl, methoxy and ethoxy.

5 16. A compound according to any one of claims 1 to 15 wherein R_2 is optionally substituted by 1 or 2 substituents selected from fluoro, chloro, amino, methyl, ethyl and methoxy.









17. A compound according to any one of claims 1 to 10 wherein
10 R_2 is of the formula:



in which R_5 is amino, hydroxy or hydrogen, and R_6 and R_7 , which may be the same or different, are halo, nitro, thiol, cyano, haloalkyl, haloalkoxy, amido, hydrazido, amino,
15 alkylthio, alkenyl, alkynyl or R_1 (as defined in claim 1) or taken together form a 5 or 6 membered fused carbocyclic ring or 5 membered heterocyclic ring, which may itself be substituted by R_{1j} (as defined in claim 1), amino, halo, cyano, nitro, thiol, alkylthio, haloalkyl or haloalkoxy.

20

18. A compound according to any one of claims 1 to 10 wherein R_2 is selected from one of the formula (A') to (H'):



wherein X_4 is O or S, R_{13} is selected from hydrogen, chloro or methyl and R_{14} is selected from hydrogen, methyl, ethyl, fluoro, chloro, and methoxy and R_{15} is selected from hydrogen, methyl, fluoro, chloro and amino.

19. A compound according to claim 18, wherein R_2 is of the formula (A') (wherein R_{14} is selected from hydrogen, methyl, ethyl, fluoro, chloro, and methoxy and R_{15} is selected from hydrogen, methyl, fluoro, chloro and amino) or of the formula (B') (wherein R_{13} is chloro) or of the formula (C') (wherein R_{13} is selected from hydrogen, methyl and chloro) or of the formula (D') (wherein R_{13} is selected from hydrogen and chloro) or of the formula (E') (wherein R_{13} is hydrogen) or of the formula (G') (wherein R_{13} is chloro).

20. A compound according to claim 18, wherein R_2 is 4-methoxyphenyl, 5-chloroindol-2-yl, 3-chloroindol-6-yl, indol-6-yl or 3-methylindol-6-yl.

5 21. A compound according to claim 19 wherein R_2 is of the formula (A') and R_{14} and R_{15} are as defined in claim 19.

22. A compound according to claim 19 wherein R_2 is of the formula (A') and R_{14} is methoxy and R_{15} is hydrogen.

10

23. A compound according to any one of claims 1 to 22 wherein -X-X- is selected from -CH=CH-, -CONH-, -CONR_{1a}-, -NH-CO-, -NH-CH₂-, -CH₂-NH-, -CH₂O-, -OCH₂-, -COO-, -OC=O- and -CH₂CH₂- wherein R_{1a} is as defined in claim 1.

15

24. A compound according to any one of claims 1 to 22 wherein -X-X- is -CONH-.

25. A compound according to any one of claims 1 to 24 wherein
20 R_{1b} is hydrogen, methyl or hydroxymethyl.

26. A compound according to any one of claims 1 to 24 wherein R_{1b} is hydrogen.

25 27. A compound according to any one of claims 1 to 26 wherein Y is CH.

28. A compound according to any one of claims 1 to 27 wherein Cy is an optionally R_{3a} substituted: phenyl, pyridyl, 30 thienyl, thiazolyl, naphthyl, piperidinyl, furanyl, pyrrolyl, isoxazolyl, isothiazolyl, pyrazolyl, oxazolyl, imidazolyl, 1,2,4-thiadiazolyl, 1,3,4-thiadiazolyl, pyrimidinyl, pyridazinyl, quinoloyl, isoquinolyl, benzofuryl, benzothienyl or cycloalkyl group, or a phenyl group substituted by $R_{3i}X_i$ in 35 which X_i is a bond, O, NH or CH₂ and R_{3i} is phenyl optionally substituted by R_{3a} .

29. A compound according to any one of claims 1 to 27

wherein Cy is an optionally R_{3a} substituted: phenyl, pyridyl, thienyl, thiazolyl, naphthyl, piperidinyl or cycloalkyl group.

30. A compound according to any one of claims 1 to 29
5 wherein R_{3a} is selected from hydrogen, hydroxyl, alkoxy, alkyl (optionally substituted by hydroxy, alkylamino, alkoxy, oxo, aryl or cycloalkyl), aminoalkyl (optionally substituted by hydroxy, alkylamino, alkoxy, oxo, aryl or cycloalkyl), hydroxyalkyl (optionally substituted by hydroxy, alkylamino,
10 alkoxy, oxo, aryl or cycloalkyl), alkoxyalkyl, alkoxycarbonyl, alkylaminocarbonyl, alkoxycarbonylamino, alkylamino (optionally substituted by hydroxy, alkylamino, alkoxy, oxo, aryl or cycloalkyl), amino, halo, cyano, nitro, thiol, alkylthio, alkylsulphonyl, alkylsulphenyl, alkylsulphonamido,
15 alkylaminosulphonyl, aminosulphonyl, haloalkoxy, haloalkyl, a group of the formula -C(X³)N(R¹¹)R¹² (wherein X³ is O or S; and R¹¹ and R¹² are independently selected from hydrogen, methyl or ethyl or together with the nitrogen atom to which they are attached form a pyrrolidin-1-yl, piperidin-1-yl or morpholino
20 group) and -OCH₂O- which is bonded to two adjacent ring atoms in Cy.

31. A compound according to any one of claims 1 to 27 wherein R_{3a} is selected from hydrogen, hydroxyl, alkoxy, alkyl
25 (optionally substituted by hydroxy, alkylamino, alkoxy, oxo, aryl or cycloalkyl), aminoalkyl (optionally substituted by hydroxy, alkylamino, alkoxy, oxo, aryl or cycloalkyl), hydroxyalkyl (optionally substituted by hydroxy, alkylamino, alkoxy, oxo, aryl or cycloalkyl), alkoxyalkyl, alkoxycarbonyl,
30 alkylaminocarbonyl, alkoxycarbonylamino, alkylamino (optionally substituted by hydroxy, alkylamino, alkoxy, oxo, aryl or cycloalkyl), amino, halo, cyano, nitro, thiol, alkylthio, alkylsulphonyl, alkylsulphenyl, alkylsulphonamido, alkylaminosulphonyl, aminosulphonyl, haloalkoxy and haloalkyl.


35

32. A compound according to any one of claims 1 to 27 wherein R_{3a} is selected from hydrogen, hydroxyl, methoxy, ethoxy, methyl, ethyl, hydroxymethyl, carboxy, methoxymethyl,

methoxycarbonyl, ethoxycarbonyl, methylaminocarbonyl,
dimethylaminocarbonyl, aminomethyl, CONH_2 , CH_2CONH_2 ,
acetyl amino, methoxycarbonylamino, ethoxycarbonylamino, t-
butoxycarbonylamino, amino, fluoro, chloro, bromo, cyano,
5 nitro, thiol, methylthio, methylsulphonyl, ethylsulphonyl,
methylsulphenyl, methylsulphonylamido, ethylsulphonylamido,
methylaminosulphonyl, ethylaminosulphonyl, aminosulphonyl,
trifluoromethoxy, trifluoromethyl, bromo, $-\text{OCH}_2\text{O}-$ (which is
bonded to two adjacent ring atoms in Cy) and $-\text{C}(\text{X}^3)\text{N}(\text{R}^{11})\text{R}^{12}$
10 (wherein X^3 is O or S and R^{11} and R^{12} are independently selected
from hydrogen, methyl or ethyl or together with the nitrogen
atom to which they are attached form a pyrrolidin-1-yl,
piperidin-1-yl or morpholino group).

15 33. A compound according to any one of claims 1 to 29 wherein
 R_{3a} is selected from hydrogen, hydroxyl, methoxy, ethoxy,
methyl, ethyl, hydroxymethyl, carboxy, methoxymethyl,
methoxycarbonyl, ethoxycarbonyl, methylaminocarbonyl,
dimethylaminocarbonyl, aminomethyl, CONH_2 , CH_2CONH_2 ,
20 acetyl amino, methoxycarbonylamino, ethoxycarbonylamino, t-
butoxycarbonylamino, amino, fluoro, chloro, cyano, nitro,
thiol, methylthio, methylsulphonyl, ethylsulphonyl,
methylsulphenyl, methylsulphonylamido, ethylsulphonylamido,
methylaminosulphonyl, ethylaminosulphonyl, aminosulphonyl,
25 trifluoromethoxy and trifluoromethyl.

34. A compound according to any one of claims 1 to 29
wherein Cy is selected from:



wherein:

X' is selected from O, S and NMe;

5 X'' is selected from O and S;

X''' is selected from O, S, NH and NMe;

Y' is selected from hydrogen, amino and methyl;

R_o is selected from hydrogen, methyl, fluoro, chloro, trifluoromethyl, methoxy, methylthio, methylsulphinyl and

10 methylsulphonyl;

R_m is selected from hydrogen, methyl, fluoro, chloro, trifluoromethyl, methoxy, methylthio, methylsulphinyl, methylsulphonyl, carboxy, methoxycarbonyl and a group of the formula $-C(X^3)N(R^{11})R^{12}$ (wherein X^3 is O or S, and R^{11} and R^{12} are

independently selected from hydrogen, methyl or ethyl or together with the nitrogen atom to which they are attached form a pyrrolidin-1-yl, piperidin-1-yl or morpholino group);

R_p is selected from hydrogen and fluoro; or

5 R_o and R_m or R_m and R_p form an $-OCH_2O-$ group; or

R_o and R_m together with the ring to which they are attached form a 5 or 6 membered aryl or heteroaryl ring (wherein the heteroaryl ring contains 1 or 2 heteroatoms selected from nitrogen, oxygen and sulfur); and

10 one of R_{o1} and R_{o2} is hydrogen and the other is R_o .

35. A compound according to any one of claims 1 to 29 wherein Cy is selected from phenyl (optionally substituted by ethyl, prop-2-yl, phenoxy, hydroxy, ethoxy, benzyloxy, prop-2-yloxy,

15 nitro, amino, acetyl amino, methylsulfonylamino, dimethylamino, chloro, methoxy, trifluoromethyl, methylthio, methylsulfonyl, tert-butylthio, tert-butylsulfonyl, aminosulfonyl or carbamoyl), pyridyl, thienyl, furanyl, imidazolyl, thiazolyl (optionally substituted by amino or methyl), naphthyl,

20 isoquinolinyl and quinolinyl.

36. A compound according to any one of claims 1 to 29 wherein Cy is selected from phenyl, 2-chlorophenyl, 2-methoxyphenyl, 4-carbamoylphenyl, pyrid-2-yl, pyrid-4-yl, thien-2-yl, thien-

25 3-yl, furan-2-yl, furan-3-yl, imidazol-2-yl, thiazol-2-yl, thiazol-4-yl, 2-amino-thiazol-4-yl, thiazol-5-yl, naph-1-thyl, isoquinolin-5-yl, isoquinolin-8-yl, quinolin-4-yl, quinolin-5-yl and quinolin-8-yl.

30 37. A compound according to any one of claims 1 to 29 wherein Cy is selected from phenyl, 2-methoxyphenyl,

4-carbamoylphenyl, pyrid-2-yl, thien-2-yl, thien-3-yl, furan-2-yl, furan-3-yl, imidazol-2-yl, thiazol-2-yl, thiazol-4-yl, thiazol-5yl and quinolin-4-yl.

35

38. A compound according to any one of claims 1 to 29 wherein Cy is phenyl.


39. A compound of the formula:



wherein Cy, R₂ and R_q are as defined in claim 1.

A B S T R A C T

Compounds of formula (I)



(I)

5 in which R_2 , X, Y, Cy, L and Lp(D)_n have the meanings given in the specification, are inhibitors of the serine protease, factor Xa and are useful in the treatment of cardiovascular
10 disorders.

ACT NO G601 / 02572

JRL-1